var title_f0_17_272="Sural nerve";
var content_f0_17_272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sural nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The sural nerve is a cutaneous nerve that is closely associated with the small saphenous vein as it travels distally to the lateral foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_272=[""].join("\n");
var outline_f0_17_272=null;
var title_f0_17_273="Anterior shoulder dislocation appearance";
var content_f0_17_273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior right shoulder dislocation in a young man",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the prominent acromion, the rounded appearance of the shoulder, and the slightly abducted and externally rotated position of the right arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_273=[""].join("\n");
var outline_f0_17_273=null;
var title_f0_17_274="Placement of meshed skin graft";
var content_f0_17_274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skinning vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The meshed skin graft is being secured. Long sutures are used to tie down a bolster dressing, thus avoiding&nbsp;graft shear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_274=[""].join("\n");
var outline_f0_17_274=null;
var title_f0_17_275="Beta blockers in the treatment of hyperthyroidism";
var content_f0_17_275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Beta blockers in the treatment of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/275/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/275/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/275/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/275/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/275/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/275/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/17/275/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many tissues, hyperthyroidism is associated with an increased number of &szlig;-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/1\">",
"     1",
"    </a>",
"    ]. The ensuing increase in &szlig;-adrenergic activity is responsible for many of the symptoms associated with this disorder. It also explains the ability of &szlig;-blockers to ameliorate rapidly many of the symptoms, including palpitations, tachycardia, tremulousness, anxiety, and heat intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    in high doses (above 160",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    also slowly decreases serum triiodothyronine (T3) concentrations by as much as 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/3\">",
"     3",
"    </a>",
"    ], via inhibition of the 5'-monodeiodinase that converts thyroxine (T4) to T3. Propranolol is highly lipid-soluble, allowing it to become sufficiently concentrated in tissues to inhibit monodeiodinase activity. This effect of propranolol is slow, occurring over 7 to 10 days, and contributes little to the therapeutic effects of the drug.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    , alprenolol, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    similarly cause minimal reductions in serum T3 concentrations, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    do not [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this theoretical advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and related drugs, the small effect and slow onset severely limit their usefulness for reducing serum T3 concentrations. If deiodinase inhibition is considered important in a patient with severe hyperthyroidism, it is best achieved by the addition of an iodinated radiocontrast agent to the medical regimen (these agents are currently not available in the US), or the use of PTU. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;&szlig;-blockers should be given to most hyperthyroid patients who do not have a contraindication to their use. Beta blockers are relatively or, depending upon disease severity, absolutely contraindicated in patients with asthma or chronic obstructive pulmonary disease, severe peripheral vascular disease, Raynaud phenomenon, bradycardia, second or third degree heart block, and hypoglycemia-prone diabetics in whom the early warning symptoms of hypoglycemia may be masked.",
"   </p>",
"   <p>",
"    In the absence of contraindications, beta blockers can be administered as soon as the diagnosis of hyperthyroidism is made, even before obtaining a 24-hour radioiodine uptake. In patients with Graves&rsquo; disease, &szlig;-blockers are typically coadministered with a thionamide, but they can be given alone in patients treated with radioiodine.",
"   </p>",
"   <p>",
"    Patients with relative contraindications to &szlig;-blockade may better tolerate &szlig;1-selective drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    . We generally use atenolol in an initial dose of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    up to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    can be given if needed for the symptomatic treatment of hyperthyroidism and control of tachycardia. Atenolol has the advantages of single daily dosing and beta-1 selectivity; however, all beta-adrenergic blocking drugs effectively diminish hyperthyroid symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &szlig;-blockers can also be used for preoperative therapy in patients who are allergic to thionamides. The longer-acting drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , provide for more constant intraoperative and postoperative control, and minimize the need for intravenous &szlig;-blocker administration during the period that the patient is unable to take oral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/5\">",
"     5",
"    </a>",
"    ]. One report demonstrated an increased spontaneous abortion risk in pregnant women with hyperthyroidism treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and a thionamide versus a thionamide alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/6\">",
"     6",
"    </a>",
"    ]. This observation raises questions about the use of &szlig;-blockers to treat hyperthyroidism during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/275/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &szlig;-blockers rapidly ameliorate many of the symptoms of hyperthyroidism, including palpitations, tachycardia, tremulousness, anxiety, and heat intolerance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assuming there are no contraindications to its use, we recommend using a beta blocker for patients with moderate-to-severe hyperadrenergic symptoms until euthyroidism is achieved by thionamides, radioiodine, or surgery (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical use'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We typically start with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg daily, and increase the dose as needed (up to 200 mg daily) to reduce pulse to under 90 beats per minute if blood pressure allows.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/1\">",
"      Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 1983; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/2\">",
"      Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/3\">",
"      Wiersinga WM, Touber JL. The influence of beta-adrenoceptor blocking agents on plasma thyroxine and triiodothyronine. J Clin Endocrinol Metab 1977; 45:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/4\">",
"      Perrild H, Hansen JM, Skovsted L, Christensen LK. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism. Clin Endocrinol (Oxf) 1983; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/5\">",
"      Gerst PH, Fildes J, Baylor P, Zonszein J. Long-acting beta-adrenergic antagonists as preparation for surgery in thyrotoxicosis. Arch Surg 1986; 121:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/275/abstract/6\">",
"      Sherif IH, Oyan WT, Bosairi S, Carrascal SM. Treatment of hyperthyroidism in pregnancy. Acta Obstet Gynecol Scand 1991; 70:461.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7874 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_275=[""].join("\n");
var outline_f0_17_275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_276="Edetate calcium disodium (calcium EDTA): Patient drug information";
var content_f0_17_276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Edetate calcium disodium (calcium EDTA): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=see_link\">",
"     see \"Edetate calcium disodium (calcium EDTA): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=see_link\">",
"     see \"Edetate calcium disodium (calcium EDTA): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Disodium Versenate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor if you have more pressure in your brain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of lead from the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to edetate calcium disodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor kidney function.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you have the right drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11359 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_276=[""].join("\n");
var outline_f0_17_276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164143\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017154\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017156\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017155\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017159\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017160\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017162\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017158\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017163\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017164\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/27/12726?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31557?source=related_link\">",
"      Edetate calcium disodium (calcium EDTA): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_277="Protein catabolic rate in maintenance dialysis";
var content_f0_17_277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein catabolic rate in maintenance dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/277/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/277/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/277/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/277/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/277/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/277/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/277/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/17/277/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein catabolic rate (PCR), also called the protein equivalent of nitrogen appearance (PNA), can be used to assess dietary protein intake in patients who are in a steady state. Suppose, for example, that a patient has a desirably low predialysis BUN. This finding could represent either a well nourished patient who is adequately dialyzed, or decreased protein intake which is usually a reflection of inadequate dialysis. The PCR will distinguish between these possibilities.",
"   </p>",
"   <p>",
"    The PCR is determined by measuring the",
"    <strong>",
"     interdialytic",
"    </strong>",
"    appearance of urea in body fluids plus any urea lost in the urine in patients with residual renal function. Retrospective data from a large group of dialysis patients indicates that abnormalities in a number of standard laboratory measurements related to patient nutrition (plasma concentrations of albumin, creatinine, urea nitrogen, and transferrin) are associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/1\">",
"     1",
"    </a>",
"    ]; however, only PCR is of value in prospectively predicting morbidity in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .) In the National Cooperative Dialysis Study (NCDS), for example, a PCR greater than 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day and a timed average urea concentration of 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (18",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were associated with low morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/2\">",
"     2",
"    </a>",
"    ]. The latter alone is insufficient, since it can be induced by a low protein intake.",
"   </p>",
"   <p>",
"    Although PCR is often viewed as a variable that can be manipulated independently, it varies directly with the",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    a measure of dialysis adequacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of a small group of hemodialysis patients, the intensity of dialysis was increased by enhancing dialysis time, blood flow,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      membrane surface area [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/3\">",
"       3",
"      </a>",
"      ]. As the",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      rose from 0.82 to 1.32 over a three month period, there was a concurrent elevation in PCR from 0.81 to 1.02",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day. The rise in PCR was indicative of increased protein intake (and better nutrition) due, presumably, to improved appetite. A second group in which the dialysis regimen was unchanged had no increase in either",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      or PCR.",
"     </li>",
"     <li>",
"      In another report, converting 13 patients from conventional dialysis (3 x 4",
"      <span class=\"nowrap\">",
"       hours/week)",
"      </span>",
"      to three times per week nocturnal dialysis (3 x 8",
"      <span class=\"nowrap\">",
"       hours/week)",
"      </span>",
"      led to a significant increase in nPCR (1.39",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day at baseline to 2.25",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day at 12 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PCR is a function of protein catabolism and reflects protein intake only if the patient is in a",
"    <strong>",
"     steady state",
"    </strong>",
"    regarding nutrition. Unless there is obvious evidence of poor nutrition (eg, PCR below 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) or underdialysis (eg,",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &lt;1,2), alterations in dialysis prescription should be undertaken only after clear trends in these parameters are apparent. This may require several months of monitoring PCR and",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    to ascertain that a significant change has occurred.",
"   </p>",
"   <p>",
"    Repeat measurements can overcome a potential problem in that the PCR is usually measured only once per month and may therefore not reflect day-to-day variations in intake [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/5\">",
"     5",
"    </a>",
"    ]. These daily changes in dietary intake, even among clinically stable dialysis patients, may be associated with widely varying PCR values. In one study of 50 such patients, for example, three measurements from a single individual were required to obtain a PCR with an error of less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a low PCR is related to increased mortality, practically all studies that have examined the relationship have used the initial or baseline level of the PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/7\">",
"     7",
"    </a>",
"    ]. To better assess the relationship between nPCR and mortality, a retrospective two year study evaluated the associations over time between dietary protein intake and survival among nearly 54,000 hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/8\">",
"     8",
"    </a>",
"    ]. Overall, increased mortality was observed with a nPNA (eg, normalized Protein equivalent of Nitrogen Appearance, which is the same as the nPCR) of less than 0.8 or greater than 1.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, while the best survival was noted with levels between 1.0 and 1.4",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Among patients with nPNA levels between 0.8 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, an increase or decrease in protein intake during the first six months was associated with increased or decreased survival over the subsequent 18 months, respectively. Thus, reduced survival is associated with an initially low PCR and decreased protein intake over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CALCULATION OF PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PCR is usually expressed as",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, a parameter that is also called the normalized PCR (nPCR). Less commonly, the PCR is not normalized to weight and is expressed as",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    PCR in patients treated with hemodialysis is routinely calculated by various urea kinetic modeling software programs. If a computer program is not available, the following simple formulas will give a good estimate of the nPCR. In one [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; (0.036 &nbsp;x &nbsp;ID rise in BUN &nbsp;x &nbsp;24)",
"    <br/>",
"    &nbsp;nPCR, in",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day &nbsp; = &nbsp; 0.22 &nbsp; + &nbsp; &nbsp; &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;ID interval (hrs)",
"   </p>",
"   <p>",
"    where the interdialytic (ID) rise in BUN (predialysis BUN minus the one to two minute postdialysis BUN from the preceding dialysis) is expressed in",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    If, for example, the interdialytic rise in BUN is 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (18",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and there are 44 hours from the end of one dialysis to the beginning of the next, then:",
"   </p>",
"   <p>",
"    &nbsp;nPCR &nbsp; = &nbsp; 0.22 &nbsp;+ &nbsp;([0.036 &nbsp;x &nbsp;50 &nbsp;x &nbsp;24] &divide; 44) &nbsp; = &nbsp; 1.20",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day",
"   </p>",
"   <p>",
"    Another formula calculates nPCR from the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    (an index of urea removal during dialysis) and the average BUN [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;nPCR &nbsp; = &nbsp; (0.0136 &nbsp;x &nbsp;F) &nbsp;+ &nbsp;0.251",
"   </p>",
"   <p>",
"    where F is equal to",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &nbsp;x &nbsp;([predialysis BUN &nbsp;+ &nbsp;postdialysis BUN] &nbsp;&divide; &nbsp;2).",
"   </p>",
"   <p>",
"    Thus, if the respective values for BUN are 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (27",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is 1.3, then:",
"   </p>",
"   <p>",
"    &nbsp;nPCR &nbsp; = &nbsp; (0.0136 &nbsp;x &nbsp;1.3 &nbsp;x &nbsp;50) &nbsp;+ &nbsp;0.251 &nbsp; = &nbsp; 1.13",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Residual renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary nitrogen loss must be accounted for in patients with residual renal function and persistent urine output. Thus, the following term must be added to the above equation for PCR:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;Urinary urea nitrogen (g) &nbsp;x &nbsp;150",
"    <br/>",
"    &nbsp;+ &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp;ID interval (hrs) &nbsp;x &nbsp;weight (kg)",
"   </p>",
"   <p>",
"    where the urinary urea nitrogen is all of the urea nitrogen excreted in a urine collection obtained from the end of one dialysis to the beginning of the next (ie, in the interdialytic interval).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These formulas",
"    <strong>",
"     cannot be used",
"    </strong>",
"    in patients treated with continuous peritoneal dialysis, since the BUN is relatively constant. In this setting, urea appearance is estimated from measurement of dialysate and urinary urea losses. Several equations have been used to estimate the PCR in continuous peritoneal dialysis; at present, we use the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;PCR &nbsp; = &nbsp; 6.25 &nbsp;x &nbsp;(Urea appearance &nbsp;+ &nbsp;1.81 &nbsp;+ &nbsp;[0.031 &nbsp;x &nbsp;lean body weight, kg])",
"   </p>",
"   <p>",
"    The last term in this formula reflects the contribution of nonurea protein metabolism. Urea appearance can be estimated from 24 hour dialysate and urine collections:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Urea appearance,",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    &nbsp; = &nbsp; (Vu &nbsp;x &nbsp;Cu) &nbsp; + &nbsp; (Vd &nbsp;x &nbsp;Cd)",
"   </p>",
"   <p>",
"    where V and C represent volume and urea concentration in the urine (u) and dialysate (d).",
"   </p>",
"   <p>",
"    The Dialysis Outcomes Quality Initiative (DOQI) guidelines for dialysis adequacy prefer the term Protein equivalent of Nitrogen Appearance (PNA) in lieu of PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OPTIMAL PCR AND THE DIALYSIS PRESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A target of 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day or higher is recommended by both American and European hemodialysis guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The optimal PCR range is therefore 1.0 to 1.4",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    but it is difficult to reach the higher end of the range and 1.0 to 1.2 is a more realistic goal. The higher range is difficult to achieve largely because protein-calorie malnutrition complicates the course of more than one-third of dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors may contribute to the development of malnutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability of the patient to change from a protein restricted to a protein rich diet after initiation of dialysis.",
"     </li>",
"     <li>",
"      The hemodialysis procedure is a catabolic event as 8 to 10 grams of protein are lost with each treatment; furthermore, patients may miss one or two of their normal meals on dialysis days.",
"     </li>",
"     <li>",
"      The misconception that a patient with a minimally acceptable",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      and a low mid-week BUN is necessarily well dialyzed. The PCR is often below the goal level in this setting, as inadequate protein intake contributes to the low BUN.",
"     </li>",
"     <li>",
"      The delivery of less than optimal dialysis via elements of dialysis not directly associated with the",
"      <span class=\"nowrap\">",
"       Kt/V,",
"      </span>",
"      such as the failure to adequately treat metabolic acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/277/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of other complicating clinical and social issues, including gastrointestinal disorders, inadequate understanding of dietary instructions, poor dentition, alcoholism, depression, concomitant debilitating diseases, and insufficient income (high biologic value protein-rich foods are expensive).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small percentage of patients have a \"high\" PCR (above 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day). The appropriate response to this finding should be to increase the dialysis prescription (ie, increase the",
"    <span class=\"nowrap\">",
"     Kt/V)",
"    </span>",
"    rather than to restrict dietary protein.",
"   </p>",
"   <p>",
"    PCR should be measured monthly along with the",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    Intensive nutritional counseling by a renal dietitian should be done monthly to help achieve a PCR between 1.0 and 1.2",
"    <span class=\"nowrap\">",
"     g/kg.",
"    </span>",
"    Adjustment of the dialysis prescription to raise the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    can also lead to improvement in the PCR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192306526\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The protein catabolic rate (PCR), also called the protein equivalent of nitrogen appearance (PNA), can be used to assess dietary protein intake in patients who are in a steady state. The PCR is determined by measuring the",
"      <strong>",
"       interdialytic",
"      </strong>",
"      appearance of urea in body fluids plus any urea lost in the urine in patients with residual renal function. Although PCR is often viewed as a variable that can be manipulated independently, it varies directly with the",
"      <span class=\"nowrap\">",
"       Kt/V,",
"      </span>",
"      a measure of dialysis adequacy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The PCR is usually expressed as",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day, a parameter that is also called the normalized PCR (nPCR). Less commonly, the PCR is not normalized to weight and is expressed as",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      A simple calculation of PCR requires only the pre and post blood urea nitrogen (BUN) and the calculated",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      obtained during a single dialysis session. Adjustments for unmeasured urinary urea losses must be made to the calculation if the patient has significant residual renal function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Calculation of PCR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the optimal PCR is 1.0 to 1.4",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      it is difficult to reach the higher end of this range, and a goal of 1.0 to 1.2 is more realistic. The PCR should be measured monthly along with the",
"      <span class=\"nowrap\">",
"       Kt/V.",
"      </span>",
"      Intensive nutritional counseling by a renal dietitian should be done monthly to help achieve goal PCR levels. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Optimal PCR and the dialysis prescription'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/1\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/2\">",
"      Laird NM, Berkey CS, Lowrie EG. Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study. Kidney Int Suppl 1983; :S101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/3\">",
"      Lindsay RM, Spanner E, Heidenheim RP, et al. Which comes first, Kt/V or PCR--chicken or egg? Kidney Int Suppl 1992; 38:S32.",
"     </a>",
"    </li>",
"    <li>",
"     David, S, Kumpers, P, Eisenbach, GM, et al. Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal stragety. Nephrol Dial Transplant 2009 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/5\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure. Guideline 8. Am J Kidney Dis 2000; 35(Suppl 2):S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/6\">",
"      Kloppenburg WD, Stegeman CA, Hooyschuur M, et al. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient. Kidney Int 1999; 55:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/7\">",
"      Combe, C, McCullough, KP, Asano, Y, et al. Kidneay Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and practices. Am J Kidney Dis 2004; 5 Suppl 3:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/8\">",
"      Shinaberger CS, Kilpatrick RD, Regidor DL, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006; 48:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/9\">",
"      Jindal, KK, Goldstein, MB. Urea kinetic modeling in chronic hemodialysis: Benefits, problems, and practical solutions. Semin Dial 1988; 1:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/10\">",
"      Lightfoot, BO, Caruana, RJ, Mulloy, LL, Fincher, ME. Simple formula for calculating normalized protein catabolic rate (NPCR) in hemodialysis (HD) patients (abstract). J Am Soc Nephrol 1993; 4:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/11\">",
"      Keshaviah PR, Nolph KD. Protein catabolic rate calculations in CAPD patients. ASAIO Trans 1991; 37:M400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/12\">",
"      Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/13\">",
"      NKF-DOQI Clinical Practice Guidelines. IV. Assessment of nutritional status specifically as it relates to peritoneal dialysis. Am J Kidney Dis 2001; 37(Suppl 1):S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/14\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure. Guideline 15. Am J Kidney Dis 2000. Am J Kidney Dis 2000; 35(Suppl 2):S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/15\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/16\">",
"      Bastani B, McNeely M, Schmitz PG. Serum bicarbonate is an independent determinant of protein catabolic rate in chronic hemodialysis. Am J Nephrol 1996; 16:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/277/abstract/17\">",
"      Lindsay RM, Bergstr&ouml;m J. Membrane biocompatibility and nutrition in maintenance haemodialysis patients. Nephrol Dial Transplant 1994; 9 Suppl 2:150.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1841 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_277=[""].join("\n");
var outline_f0_17_277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H192306526\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CALCULATION OF PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Residual renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OPTIMAL PCR AND THE DIALYSIS PRESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192306526\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_278="Surgical treatment of midpalmar space abscess";
var content_f0_17_278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Surgical treatment of midpalmar space abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The surgical approach to a mid-palmar space abscess is shown in panel A. The debridement of a mid-palmar space abscess is shown in panel B.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_278=[""].join("\n");
var outline_f0_17_278=null;
var title_f0_17_279="Autoimmune chronic hepatitis in a 21-year-old - low power";
var content_f0_17_279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Autoimmune chronic hepatitis in a 21-year-old man who failed to take prednisone and azathioprine as prescribed (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is extensive scarring and nodule formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dufour J, DelEllis R, Kaplan MM. Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis. Ann Intern Med 1997; 127:981. Copyright &copy; 1997 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_279=[""].join("\n");
var outline_f0_17_279=null;
var title_f0_17_280="Sitagliptin and simvastatin: Drug information";
var content_f0_17_280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sitagliptin and simvastatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/53/36693?source=see_link\">",
"    see \"Sitagliptin and simvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13458345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Juvisync&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13276822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor;",
"     </li>",
"     <li>",
"      Antilipemic Agent, HMG-CoA Reductase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13317032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperlipidemia and type 2 diabetes:",
"     </b>",
"     Oral: Initial dose: Sitagliptin 100 mg and simvastatin 40 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Patients already taking simvastatin &lt;40 mg daily (with or without sitagliptin 100 mg daily) can be converted to the comparable equivalent of the combination product.  Dose adjustments should be made at intervals of &ge;4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Concomitant use with insulin and/or insulin secretagogues (eg, sulfonylureas):",
"     </i>",
"     Reduced dose of insulin and/or insulin secretagogues may be needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for simvastatin with concomitant medications:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Amiodarone, amlodipine, or ranolazine: Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 20 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diltiazem, dronedarone, or verapamil: Simvastatin dose should",
"     <b>",
"      not",
"     </b>",
"     exceed 10 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for simvastatin in Chinese patients on niacin doses &ge;1 g/day:",
"     </i>",
"     Use caution with simvastatin doses of 40 mg/day because of an increased risk of myopathy",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13317034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function may be estimated using Cockcroft-Gault formula for dosage adjustment purposes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 to &lt;50 mL/minute (approximate S",
"     <sub>",
"      cr",
"     </sub>",
"     of &gt;1.7 to &le;3.0 mg/dL [males] or &gt;1.5 to &le;2.5 mg/dL [females]): Initial: Sitagliptin 50 mg and simvastatin 40 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Patients already taking simvastatin &lt;40 mg daily (with or without sitagliptin 50 mg daily) can be converted to the comparable equivalent of the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (approximate S",
"     <sub>",
"      cr",
"     </sub>",
"     of &gt;3.0 mg/dL [males] or &gt;2.5 mg/dL [females]): Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     End-stage renal disease (ESRD): Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13317033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13317227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 50/10: Sitagliptin 50 mg and simvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 50/20: Sitagliptin 50 mg and simvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 50/40: Sitagliptin 50 mg and simvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 100/10: Sitagliptin 100 mg and simvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 100/20: Sitagliptin 100 mg and simvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Juvisync&trade; 100/40: Sitagliptin 100 mg and simvastatin 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13317011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13317010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM275945.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM275945.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13317037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer in the evening.  Do not split or divide tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13276824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use when treatment with both sitagliptin and simvastatin is appropriate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitagliptin: Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination therapy with other antidiabetic agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Used with dietary therapy for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary prevention of cardiovascular events in hypercholesterolemic patients with established coronary heart disease (CHD) or at high risk for CHD: To reduce cardiovascular morbidity (myocardial infarction, coronary/noncoronary revascularization procedures) and mortality; to reduce the risk of stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyperlipidemias: To reduce elevations in total cholesterol (total-C), LDL-C, apolipoprotein B, triglycerides, and VLDL-C, and to increase HDL-C in patients with primary hypercholesterolemia (elevations of 1 or more components are present in Fredrickson type IIa, IIb, III, and IV hyperlipidemias); treatment of homozygous familial hypercholesterolemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14198961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13317020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13317016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to simvastatin, sitagliptin, or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, protease inhibitors [including boceprevir and telaprevir], itraconazole, ketoconazole, nefazodone, posaconazole, voriconazole, telithromycin), cyclosporine, danazol, or gemfibrozil",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13317017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus: Increases in Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and fasting blood glucose have been reported with HMG-CoA reductase inhibitors; however, the benefits of statin therapy far outweigh the risk of dysglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Postmarketing reports of fatal and nonfatal hepatic failure with simvastatin are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy. If an alternate etiology is not identified, do not restart simvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated; routine periodic monitoring of liver enzymes is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylaxis, angioedema, and/or severe dermatologic reactions such as Stevens-Johnson syndrome, have been reported with sitagliptin in postmarketing surveillance; discontinue if signs/symptoms of hypersensitivity reactions occur. Events have generally been noted within the first 3 months of therapy, and may occur with the initial dose. Use with caution if patient has experienced angioedema with other DPP-IV inhibitor use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune-mediated necrotizing myopathy (IMNM): IMNM, an autoimmune-mediated myopathy, has been reported (rarely) with HMG-CoA reductase inhibitor therapy.  IMNM presents as proximal muscle weakness with elevated CPK levels, which persists despite discontinuation of HMG-CoA reductase inhibitor therapy; additionally, muscle biopsy may show necrotizing myopathy with limited inflammation.  Immunosuppressive therapy (eg, corticosteroids, azathioprine) may be used for treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myopathy/rhabdomyolysis: Patients receiving HMG-CoA reductase inhibitors have developed rhabdomyolysis with acute renal failure and/or myopathy; patients should be monitored closely. This risk is dose-related and is increased with high doses (80 mg), concurrent use of other lipid-lowering medications (fibric acid derivatives, or niacin at doses &ge;1 g/day), other interacting drugs (eg, moderate-to-strong CYP3A4 inhibitors), age &ge;65 years, female gender, uncontrolled hypothyroidism, and renal dysfunction. Use with caution in patients taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute or serious condition predisposing to renal failure (eg, sepsis, hypotension, trauma, uncontrolled seizures). However, based upon current evidence, HMG-CoA reductase inhibitor therapy should be continued in the perioperative period unless risk outweighs cardioprotective benefit. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported with sitagliptin use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate management. Use with caution in patients with a history of pancreatitis as it is not known if this population is at greater risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetic ketoacidosis (DKA): Should not be used in patients with DKA due to lack of efficacy in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use is not recommended in patients with severe renal dysfunction and end-stage renal disease (ESRD) requiring hemodialysis since the appropriate combination dose is not available. Additionally, cases of sitagliptin-induced acute renal failure (some requiring dialysis) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Type 1 diabetes mellitus: Should not be used in patients with type 1 diabetes mellitus (insulin dependent, IDDM) due to lack of efficacy in this patient population",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: If concurrent use of a contraindicated interacting medication is unavoidable, treatment with simvastatin should be suspended during use or consider the use of an alternative HMG-CoA reductase inhibitor void of CYP3A4 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Concomitant use of insulin may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of insulin may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea) may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chinese patients: Use higher simvastatin dose (40 mg) with caution if concurrently taking niacin &ge;1 g/day; concomitant use may increase risk of myopathy in Chinese patients; risk to other Asian populations is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; these patients are predisposed to myopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy. Simvastatin has not been studied in Fredrickson type I and V hyperlipidemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13320172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13320171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: SitaGLIPtin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13317023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid excessive ethanol consumption (due to potential hepatic effects).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Simvastatin serum concentration may be increased when taken with grapefruit juice; avoid concurrent intake of large quantities (&gt;1 quart/day).  Red yeast rice contains an estimated 2.4 mg lovastatin per 600 mg rice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease simvastatin levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13317012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13317013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13317014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13317015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13317036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Juvisync Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-10 mg (30): $295.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-20 mg (30): $295.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-40 mg (30): $295.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-10 mg (90): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-20 mg (90): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-40 mg (90): $885.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13317039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , serum glucose; renal function (prior to initiation and periodically during treatment); baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy; discontinue therapy if markedly elevated); baseline liver function tests (LFTs) and repeat when clinically indicated thereafter. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize; discontinue if increase in ALT/AST is persistently &gt;3 times ULN (NCEP, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Lipid panel (total cholesterol, HDL, LDL, triglycerides):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      ATP III recommendations (NCEP, 2002):",
"     </i>",
"     Baseline; 6-8 weeks after initiation of drug therapy; if dose increased, then at 6-8 weeks until final dose determined. Once treatment goal achieved, follow up intervals may be reduced to every 4-6 months. Lipid panel should be assessed at least annually, and preferably at each clinic visit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Manufacturer recommendation:",
"     </i>",
"     Upon initiation or titration, lipid panel should be analyzed after &ge;4 weeks of therapy and periodically thereafter.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F15657898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13317026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Simvastatin: A methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Sitagliptin: Inhibits dipeptidyl peptidase IV (DPP-IV) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-IV enzyme.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13317028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/17/280/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castro C and Gourley M, \"Diagnosis and Treatment of Inflammatory Myopathy: Issues and Management,\"",
"      <i>",
"       Ther Adv Musculoskelet Dis",
"      </i>",
"      , 2012, 4(2):111-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/17/280/abstract-text/22870499/pubmed\" id=\"22870499\" target=\"_blank\">",
"        22870499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/17/280/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17090 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_280=[""].join("\n");
var outline_f0_17_280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339642\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13458345\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276822\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317032\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317034\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317033\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317227\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317011\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317010\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317037\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276824\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14198961\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317020\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317016\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317017\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320172\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13320171\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317023\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317012\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317013\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317014\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317015\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317036\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322918\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317039\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15657898\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317026\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13317028\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17090\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17090|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/53/36693?source=related_link\">",
"      Sitagliptin and simvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_281="Definition and screening for dyslipidemia in children";
var content_f0_17_281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and screening for dyslipidemia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/281/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/281/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/281/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/281/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/17/281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H235228225\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemias are disorders of lipoprotein metabolism that result in the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High total cholesterol (TC)",
"     </li>",
"     <li>",
"      High low-density lipoprotein cholesterol (LDL-C)",
"     </li>",
"     <li>",
"      Low high-density lipoprotein cholesterol (HDL-C)",
"     </li>",
"     <li>",
"      High triglycerides (TG)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In adults, dyslipidemia is an established risk factor for cardiovascular disease (CVD), and correcting dyslipidemia reduces the risk of CVD. The effect of treatment rises as the risk of CVD increases, with the greatest benefit in adults with known coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dyslipidemia often begin in childhood and adolescence. Pediatric dyslipidemia contributes to early atherosclerosis, and by extrapolation to premature CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. Moreover, in the high-risk subset of children with severe dyslipidemia due to homozygous hypercholesterolemia, treatment reduces the risk of cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although long-term intervention trials for dyslipidemia in children have not been performed, it is reasonable to assume based on the evidence from adult studies and prospective cohort studies beginning in childhood that timely intervention to decrease and, possibly, eliminate dyslipidemia in children may slow the atherosclerotic process, delaying the onset of CVD. As a result, identifying children with dyslipidemia and successfully improving their lipid profile may reduce their risk of accelerated atherosclerosis and premature CVD.",
"   </p>",
"   <p>",
"    The association between pediatric dyslipidemia and atherosclerosis, definition of pediatric dyslipidemia, and screening to identify children with lipid disorders will be reviewed here. Primary pediatric preventive measures to reduce or prevent premature atherosclerosis, and the management of children with dyslipidemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728055\">",
"    <span class=\"h1\">",
"     ASSOCIATION BETWEEN PEDIATRIC DYSLIPIDEMIA AND ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct evidence from pediatric autopsy studies and data using indirect measures of atherosclerosis have shown a relationship between lipid disorders in children and the early onset of atherosclerosis, as demonstrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In both the Bogalusa Heart and Pathobiological Determinants of Atherosclerosis in Youth studies, autopsy findings in children and young adults who died of noncardiovascular causes demonstrated an increase in atherosclerotic lesions in the coronary artery and aorta with increasing total cholesterol (TC), serum LDL-C, and non-HDL-C, and decreasing serum HDL-C [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children, abnormal levels of lipids and lipoproteins are associated with indirect markers of atherosclerosis including endothelial dysfunction assessed by flow-mediated dilation (FMD) in the brachial artery and increased carotid intima-media thickness (cIMT) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. Pediatric elevations of TC, non-HDL-C, LDL-C, TG, and the ratio of",
"      <span class=\"nowrap\">",
"       TC/HDL-C",
"      </span>",
"      are correlated with increased cIMT and coronary artery calcium during adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/8\">",
"       8",
"      </a>",
"      ]. Increased pediatric levels of apolipoprotein B and the ratio of apolipoprotein",
"      <span class=\"nowrap\">",
"       B/apolipoprotein",
"      </span>",
"      A-I are also associated with increased adult IMT [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other support for pediatric dyslipidemia as a risk factor for CVD includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tracking of pediatric lipid disorders into adulthood &mdash; Approximately half of the children with abnormal serum lipoprotein values will continue to have elevated lipid levels into adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1,10-12\">",
"       1,10-12",
"      </a>",
"      ]. Children with severely elevated lipid values consistent with familial hyperlipidemia have even more consistent tracking over time through adulthood. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children's lipid values correlate with those of adult family members, and children with dyslipidemia are more commonly found in families with CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with heterozygous or homozygous familial hypercholesterolemia, reducing LDL-C levels in childhood delays the atherosclerotic process as detected by indirect measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H894519#H894519\">",
"       \"Management of pediatric dyslipidemia\", section on 'Rationale for intervention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H728251\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of dyslipidemia can be categorized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monogenic conditions due to a single gene defect, such as familial hypercholesterolemia, familial defective apolipoprotein B, and familial hypertriglyceridemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"       \"Approach to the patient with hypertriglyceridemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary dyslipidemia related to specific diseases, such as nephrotic syndrome, type 2 diabetes mellitus, or drugs (eg, alcohol,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/33/19991?source=see_link\">",
"       isotretinoin",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef71294 \" href=\"UTD.htm?43/24/44428\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=see_link\">",
"       \"Secondary causes of dyslipidemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic, related to polygenic defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H19#H19\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Polygenic hypercholesterolemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235228232\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68566256\">",
"    <span class=\"h2\">",
"     Normative values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, normal pediatric values for lipoproteins are derived from population-based data from the Lipid Research Clinical (LRC) Prevalence Study, which obtained fasting lipoprotein profiles from 15,626 children (age range, 0 to 19 years) between 1972 and 1976 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/14\">",
"     14",
"    </a>",
"    ], and from the United States National Health and Nutrition Examination Surveys (NHANES), which collected lipid levels in 7000 children from 1988 to 1994 (",
"    <a class=\"graphic graphic_table graphicRef59427 \" href=\"UTD.htm?35/34/36397\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data and results from other studies demonstrate that pediatric lipid levels vary with gender, ethnicity, and age [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      African-American children have higher TC and HDL&ndash;C levels and lower TG levels compared with the other",
"      <span class=\"nowrap\">",
"       racial/ethnic",
"      </span>",
"      groups. However, the levels do not appear to be different in regards to the risk of atherosclerosis (as measured by cIMT) between African American children and those of other ethnicity.",
"     </li>",
"     <li>",
"      Lipid levels change with normal growth and maturation. Lipoproteins are very low in cord blood at birth and rise slowly in the first two years of life. Lipid and levels are relatively stable from two years of age until adolescence. During puberty, TC and LDL&ndash;C levels decrease with increasing age before rising in the late-teen years. Males experience a decrease in HDL levels during late puberty, whereas HDL levels remain stable in females until menopause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, normative percentiles have been developed based on age and gender. The American Academy of Pediatrics and a 2011 expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) have defined acceptable, borderline high, and elevated lipid levels based on these normative data as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1,19-21\">",
"     1,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68566413\">",
"    <span class=\"h2\">",
"     Definition of pediatric dyslipidemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432292\">",
"    <span class=\"h3\">",
"     NHLBI panel definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, an expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) further revised cutoff points, initially developed by the American Academy of Pediatrics (AAP) and the National Cholesterol Education Program (NCEP) based on population distributions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1,19-22\">",
"     1,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cutoff points delineate lipid values as acceptable, borderline, and abnormal, and are based on the above normative data. We use the NHLBI definition in our practice. However, it should be noted that these cutoff points have not been validated as accurate predictors for accelerated atherosclerosis or CVD events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/23\">",
"     23",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef68183 \" href=\"UTD.htm?42/51/43836\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acceptable: Acceptable values are below the 75",
"      <sup>",
"       th",
"      </sup>",
"      percentile except for HDL, which are above the 20",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TC &lt;170",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL-C &lt;110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Non-HDL-C &lt;120",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      TG (children 0 to 9 years) &lt;75",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"       <br/>",
"       <br/>",
"       TG",
"      </span>",
"      (adolescents 10 to 19 years) &lt;90",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C &gt;45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Borderline: Borderline normal values are between the 75",
"      <sup>",
"       th",
"      </sup>",
"      and 95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, except for HDL which is between 10",
"      <sup>",
"       th",
"      </sup>",
"      to 25",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TC: 170 to 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.4 to 5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL-C: 110 to 129",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.9 to 3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Non-HDL-C: 120 to 144",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.1 to 3.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      TG (children 0 to 9 years): 75 to 99",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.8 to 1.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"       <br/>",
"       <br/>",
"       TG",
"      </span>",
"      (adolescents 10 to 19 years): 90 to 129",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1 to 1.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C: 40 to 45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0 to 1.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      value between 10",
"      <sup>",
"       th",
"      </sup>",
"      to 25",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal: Abnormal values are &gt;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile, except for HDL, which is less than 10",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TC &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL-C &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Non-HDL-C &gt;145",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      TG (children 0 to 9 years) &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"       <br/>",
"       <br/>",
"       TG",
"      </span>",
"      (adolescents 10 to 19 years) &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      value below the 10",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66231589\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, although the rate of pediatric dyslipidemia remains concerning, data from the National Health and Nutrition Examination Survey (NHANES) involving more than 16,000 participants (ages between 6 and 19 years) showed improving mean lipid levels and rates of dyslipidemia from 1988-1994 to 2007-2010 as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean serum total cholesterol (TC) declined from 165 to 160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the prevalence of elevated TC (&ge;200",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      decreased from 11.3 to 8.1 percent.",
"     </li>",
"     <li>",
"      Mean serum HDL-C increased from 50.5 to 52.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the prevalence of low HDL-C (&lt;40",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      decreased 17.3 to 14.8 percent, but this was not statistically significant. &nbsp;",
"     </li>",
"     <li>",
"      Mean serum LDL-C levels in adolescents (ages 12 to 19 years) decreased from 95 to 90",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the prevalence of elevated LDL-C (&ge;130",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      decreased from 11.9 to 7.4 percent.",
"     </li>",
"     <li>",
"      Mean serum TG in adolescents decreased from 82 to 73",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the prevalence of elevated TG (&ge;130",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      decreased from 17.3 to 12.4 percent.",
"     </li>",
"     <li>",
"      Mean serum non-HDL-C improved from 115 to 107",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the prevalence of high non-HDL C levels (&ge;145",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      decreased from 13.6 to 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a previous analysis of NHANES from 1996-2006, the likelihood of dyslipidemia was higher in adolescents with greater body mass index (BMI); prevalence increased from 14.2 to 22.3 to 42.9 percent for youths who were normal weight, overweight (BMI 85",
"    <sup>",
"     th",
"    </sup>",
"    to 95",
"    <sup>",
"     th",
"    </sup>",
"    percentile), and obese (BMI &gt;95",
"    <sup>",
"     th",
"    </sup>",
"    percentile), respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/25\">",
"     25",
"    </a>",
"    ]. Overall, 32 percent of the youths were either overweight (15 percent) or obese (17 percent). The more recent analyses also separately assessed obese individuals and found similar declines of mean levels of TC, non-HDL-C, LDL-C and TG between the two study periods of 1988-1994 and 2007-2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause(s) of the improvements between 1988-1994 and 2007-2010 are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. Explanations proposed by the authors and a commentary include decreases in trans-fat in the food supply, less environmental smoke exposure, and possibly improved individual dietary choice. Because, few pediatric patients meet criteria for pharmacotherapy for dyslipidemia, the authors did not think that the use of medications contributed substantially to the changes in lipid levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link&amp;anchor=H86015195#H86015195\">",
"     \"Management of pediatric dyslipidemia\", section on 'Hypercholesteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235228239\">",
"    <span class=\"h1\">",
"     LIPID SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4809106\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is common in regular pediatric care and is designed to identify conditions that if untreated, result in substantial sequelae, and for which there is an available cost-effective intervention. When deciding whether screening should be performed, the sensitivity, specificity, and cost of the screening test, and the potential benefits and harms of screening and intervention must be considered. &nbsp;",
"   </p>",
"   <p>",
"    Screening for lipid disorders in children is based on the rationale that early identification and control of pediatric dyslipidemia will reduce the risk and severity of CVD in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. Lipid disorders are clinically silent in the vast majority of cases, and the criteria for selective screening miss children with lipid disorders (see",
"    <a class=\"local\" href=\"#H960344\">",
"     'Family history: Insensitive predictor'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6272034\">",
"     'Universal screening'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. In pediatric dyslipidemia, however, randomized controlled trials have not been conducted to determine whether screening and treatment are beneficial, and data are limited on the cost-effectiveness and",
"    <span class=\"nowrap\">",
"     cost/benefit",
"    </span>",
"    of various lipid screening methods. Because the cost-effectiveness of screening for pediatric dyslipidemia is uncertain, controversy continues regarding whether or not, and how, screening for pediatric dyslipidemia should be performed. This includes who should be screened, and the method and timing of screening.",
"   </p>",
"   <p>",
"    Nevertheless, after review of the current literature, the 2011 United States National Heart, Lung, and Blood Institute (NHLBI) expert panel published guidelines that recommend screening for pediatric dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines recommended combining the two complimentary approaches of selective and universal screening. (See",
"    <a class=\"local\" href=\"#H6271992\">",
"     '2011 NHLBI guidelines on pediatric lipid screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960344\">",
"    <span class=\"h3\">",
"     Family history: Insensitive predictor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, family history has been used as an important indicator for pediatric lipid screening. A family history of premature coronary artery disease in first degree relative (ie, heart attack, treated angina, interventions for coronary artery disease, stroke, or sudden cardiac disease in a male parent or sibling before 55 years of age, or a female parent or sibling before 65 years of age) has been used as a marker for pediatric dyslipidemia, and a tool for selective screening. However, both the United State Preventive Services Task Force (USPSTF) and NHLBI sponsored panel reviews concluded that using a family history of premature CVD to screen for dyslipidemia misses a significant percentage (30 to 60 percent) of children with dyslipidemia (who do not have a positive family history) including those who may warrant pharmacologic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. In addition, the current use of primary therapies for hyperlipidemia in adults, such as statin therapy, has lowered the rate of clinical cardiovascular events, which may contribute to a family history of premature CVD being less predictive of pediatric lipid levels.",
"   </p>",
"   <p>",
"    This was best illustrated by a population-based study of 20,266 fifth-grade children enrolled in the West Virginia public school system in which the rate of abnormal low-density lipoprotein cholesterol (LDL) levels in children with positive family history was similar to those found in children without concerning family history [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite being an insensitive predictor, a positive family history of premature coronary artery disease doubles the risk of CVD in children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/22,29\">",
"     22,29",
"    </a>",
"    ], and is a well-established CVD risk factor in adults. As a result, children with a positive family history are at risk for CVD and should be selectively screened for lipid disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Family history'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6272095\">",
"     'Selective screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6271992\">",
"    <span class=\"h2\">",
"     2011 NHLBI guidelines on pediatric lipid screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the executive report and summary of the Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents were published. This panel, sponsored by the United States NHLBI, reviewed the evidence on many aspects of cardiovascular health in childhood and adolescence, graded and summarized that evidence, and produced guidelines for pediatric care. These new guidelines included a major change that recommended age-specific universal screening for pediatric dyslipidemia (",
"    <a class=\"graphic graphic_table graphicRef76041 \" href=\"UTD.htm?5/39/5757\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ] diverging from previous recommendations by the American Academy of Pediatrics (AAP), the National Cholesterol Education Program (NCEP) and the USPSTF for selective screening [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/22,27,30\">",
"     22,27,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6272034\">",
"    <span class=\"h3\">",
"     Universal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NHLBI Expert Panel recommended universal screening based on their review of the literature that found sufficient evidence to support the importance of early identification to control dyslipidemia, and possibly reduce CVD risk and severity in adult life. The lack of an accurate clinical marker to aid in selective screening supports this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2011 NHLBI guidelines, screening is recommended for all children at two different time intervals (",
"    <a class=\"graphic graphic_table graphicRef76041 \" href=\"UTD.htm?5/39/5757\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First screening performed between 9 and 11 years of age before puberty because this is a stable time for lipid assessment for children.",
"     </li>",
"     <li>",
"      Second screening performed between 17 and 21 years of age after most individuals reach puberty as to avoid the changes in high-density lipoprotein (HDL-C) and LDL-C that occur during puberty and growth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6272095\">",
"    <span class=\"h3\">",
"     Selective screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pace and extent of childhood atherosclerosis (and by extension the risk of CVD) increases as the number of CVD risk factors increases. For this reason, children with one or more known atherosclerotic risk factors or with an underlying primary disease associated with increased risk for CVD should be screened for dyslipidemia. Screening can begin as early as two years of age in children at risk for CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1,31\">",
"     1,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selective screening should be performed before or in-between the recommended time periods for universal screening for the following indications (",
"    <a class=\"graphic graphic_table graphicRef76041 \" href=\"UTD.htm?5/39/5757\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive family history of premature coronary artery disease (see",
"      <a class=\"local\" href=\"#H960344\">",
"       'Family history: Insensitive predictor'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Specific conditions (eg, diabetes mellitus and familial hypercholesterolemia) associated with high- or moderate-risk of CVD (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parent with known dyslipidemia or TC &gt;240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Significant tobacco smoke exposure",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Elevated body mass index (BMI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children between two and eight years of age with a BMI &ge;95",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"     <li>",
"      Older children BMI &ge;85",
"      <sup>",
"       th",
"      </sup>",
"      percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960544\">",
"    <span class=\"h2\">",
"     Which screening test?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NHLBI guidelines allow the use of either fasting lipid profiles or non-fasting non-HDL for universal pediatric screening in children [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. In children without any known risk factors for CVD, non-HDL C testing is our preferred method. For children tested under selective screening criteria, a fasting lipid profile is recommended by NHLBI as the first screen.",
"   </p>",
"   <p>",
"    Non-HDL cholesterol is defined as the difference between the total cholesterol and HDL-C. Non-HDL cholesterol includes all cholesterol present in lipoprotein particles that are considered atherogenic, including LDL-C, lipoprotein(a), intermediate-density lipoprotein, and very-low-density lipoprotein. TC and HDL-C can be measured accurately in plasma from non-fasting individuals, making it a more practical screening test for pediatric patients than a fasting lipid profile.",
"   </p>",
"   <p>",
"    Non-fasting non-HDL C levels are increasingly used in adults and also appear to be sensitive screening tests in children for lipid disorders and early atherosclerotic changes as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis from the Bogalusa study, non-HDL C was at least as good a predictor as other lipid tests (ie, LDL-C, TC, HDL-C, and the ratio of",
"      <span class=\"nowrap\">",
"       TC/HDL-C)",
"      </span>",
"      for increased carotid intima-media thickness (an indirect marker for atherosclerosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/32\">",
"       32",
"      </a>",
"      ]. A second report from the Bogalusa study found abnormal levels of childhood non-HDL C persisted into adulthood and were predictive of adult dyslipidemia independent of baseline BMI and BMI changes over 27 years [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Pathobiological Determinants of Atherosclerosis in Youth study (PDAY study), non-HDL-C and HDL-C levels were the best lipid predictors of pathologic atherosclerotic lesions in autopsies of children who had died from noncardiac causes [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86015453\">",
"    <span class=\"h3\">",
"     Confirmation testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the non-HDL C screening test is abnormal, the NHLBI guidelines recommend that fasting lipid profiles be measured at least twice at intervals between two weeks and three months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"     1",
"    </a>",
"    ]. The average values of these lipid profiles are used to determine the need for therapeutic interventions. If the initial test is a fasting lipid profile, this should similarly be repeated at least once and averaged to determine the need for treatment. Repeated testing is required because there can be significant shifts in lipid levels in individuals.",
"   </p>",
"   <p>",
"    This was illustrated in a report from the Bogalusa study of 6827 adolescents who underwent multiple LDL-C measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/35\">",
"     35",
"    </a>",
"    ]. In children with initially elevated LDL-C levels (&gt;160",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    values decreased on average by 21",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and in those with very high initial LDL-C levels (&gt;190",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    the average decrease was 34",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Families should be counseled in lifestyle modification if any values are abnormal to promote normalization of values between testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6272158\">",
"    <span class=\"h2\">",
"     Screening controversies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for lipid disorders during childhood, especially universal screening, is controversial as demonstrated by the diversity of published recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 report, the United States Preventive Services Task Force (USPSTF), after review of the available literature, concluded that data were insufficient to make a definitive recommendation for universal screening in children and adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/27,30\">",
"       27,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2011 NHLBI guidelines recommend universal screening, in part based on the concept of identifying and treating the greatest number of individuals with familial hypercholesterolemia, a group at high risk for significant morbidity and early mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/36\">",
"       36",
"      </a>",
"      ]. However, in a dissenting opinion, one of the authors asserted that universal screening should",
"      <strong>",
"       not",
"      </strong>",
"      be performed as it would identify a large number of patients who may be harmed by screening (ie, further testing and initiation of drug therapy of questionable benefit and known adverse effects) and only a limited number of children for whom there is potential but uncertain benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others concerned about the potential negative impact of universal screening pointed to the lack of evidence that long-term, perhaps lifelong, drug treatment beginning in childhood reduces premature CVD and questioned the wisdom of using lipid levels as a screening test for premature CVD [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. They also noted that universal screening based on lipid levels note is likely to result in an estimated 200,000 pediatric patients who may qualify for drug therapy, particularly statins, which have a small but important risk of rhabdomyolysis and may be related increased rates of diabetes mellitus type 2. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H11#H11\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More data are needed to address these important questions and determine whether there is overall benefit for universal screening of pediatric dyslipidemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H235228246\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite, the above concerns, our approach to pediatric screening for dyslipidemia is consistent with the recommendations of the NHLBI expert panel.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the paucity of data on cost-effectiveness and long-term benefit, we suggest using a combined approach of universal and selective screening based on the indications and age intervals recommended by the NHLBI expert panel (",
"      <a class=\"graphic graphic_table graphicRef76041 \" href=\"UTD.htm?5/39/5757\">",
"       table 4",
"      </a>",
"      ). We base this approach on the observation that selective screening alone will fail to identify a substantial number of children with lipid disorders.",
"     </li>",
"     <li>",
"      For universal screening, we suggest that non-fasting, non-HDL C is used to screen for lipid disorders.",
"     </li>",
"     <li>",
"      For selective screening, a fasting lipid profile is ideal and is endorsed by the NHLBI guidelines as the initial screening test. However, we believe that it is reasonable to perform a non-fasting profile (ie, non-HDL C testing) in the subset of patients who are unlikely or have difficulty in complying with the recommendation for fasting testing. Data from the National Health and Nutrition Examination Survey (1999 to 2008) demonstrate small differences between non-fasting and fasting measurements that are likely clinically insignificant. These results and the absence of data demonstrating any differences in efficacy between the two methods of screening support the use of non-fasting specimens to screen for dyslipidemia, thereby eliminating the need for a fasting lipid profile, one of the major barriers of pediatric lipid screening.",
"      <br/>",
"      <br/>",
"      In patients with abnormal non-HDL C, fasting lipid testing should be performed on two separate occasions (between two and three months after the initial screen) to confirm a diagnosis of dyslipidemia.",
"      <br/>",
"      <br/>",
"      We do not recommend the use of a direct LDL as a screen because of systematic errors in these assays compared to fasting lipid profiles (this type of testing is helpful only for patients with TG&gt; 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in whom the Friedewald calculation of LDL-C is not valid) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/281/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We suggest selective screening for children at risk for CVD including children with a positive family history for early onset CVD and dyslipidemia, or who have one of the following conditions associated with risk of CVD: type 1 and 2 diabetes mellitus, nephrotic syndrome, chronic renal disease, hypertension, history of Kawasaki disease with coronary aneurysms or childhood cancer, evidence of insulin resistance, some forms of congenital heart disease (eg, coarctation of the aorta or d-transposition of the great arteries), chronic inflammatory conditions such as juvenile idiopathic arthritis (also referred to as juvenile rheumatoid arthritis) or inflammatory bowel disease, and",
"      <span class=\"nowrap\">",
"       overweight/obesity.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"       \"Diseases associated with atherosclerosis in childhood\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H31#H31\">",
"       \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Screening for dyslipidemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=see_link&amp;anchor=H6#H6\">",
"       \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\", section on 'Dyslipidemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Dyslipidemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical evaluation of the obese child and adolescent\", section on 'Laboratory studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H896751\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct evidence from pediatric autopsy studies and indirect measures of atherosclerosis demonstrate an association between lipid disorders in children and evidence of atherosclerosis in childhood. (See",
"      <a class=\"local\" href=\"#H728055\">",
"       'Association between pediatric dyslipidemia and atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of pediatric dyslipidemia includes monogenic conditions (eg, familial hypercholesterolemia), secondary causes (",
"      <a class=\"graphic graphic_table graphicRef71294 \" href=\"UTD.htm?43/24/44428\">",
"       table 1",
"      </a>",
"      ), and polygenic defects. (See",
"      <a class=\"local\" href=\"#H728251\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, the prevalence of dyslipidemia in adolescents is estimated to be about 20 percent. The likelihood of dyslipidemia increases as the body mass index rises. (See",
"      <a class=\"local\" href=\"#H66231589\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, the American Academy of Pediatrics and an expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) have defined acceptable and abnormal lipid levels based upon the normative distribution of lipids in healthy children (",
"      <a class=\"graphic graphic_table graphicRef68183 \" href=\"UTD.htm?42/51/43836\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H235228232\">",
"       'Definition'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In our practice, we use the following NHLBI thresholds to define abnormal lipids as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Total cholesterol (TC) &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      LDL-C &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      HDL-C &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Non-HDL- C &gt;145",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Triglyceride &gt;130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in children greater than 10 years of age and &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.47",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in younger children",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for lipid disorders in children is based on the rationale that early identification and control of pediatric dyslipidemia will reduce the risk and severity of cardiovascular disease (CVD) in adulthood. However, it remains uncertain whether identification and treatment of pediatric dyslipidemia with the current therapeutic options (eg, lifestyle, statin therapy) are cost-effective in reducing the risk of early CVD events. In addition, many aspects of routine pediatric screening remain controversial, including who should be screened, which screening test should be used, and when and how frequently screening should be performed. More research is needed to answer these questions. (See",
"      <a class=\"local\" href=\"#H235228239\">",
"       'Lipid screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 2011 NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk reduction in Children and Adolescents recommends both age-based universal and selective screening for pediatric dyslipidemia (",
"      <a class=\"graphic graphic_table graphicRef76041 \" href=\"UTD.htm?5/39/5757\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6271992\">",
"       '2011 NHLBI guidelines on pediatric lipid screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our practice is consistent with the NHLBI expert panel&rsquo;s approach of combining universal and selective screening to identify children with lipid disorders. Others, however, have questioned the overall cost-effectiveness of screening for pediatric dyslipidemia.",
"      <br/>",
"      <br/>",
"      We suggest the following approach based on the National Heart, Lung, and Blood Institute (NHLBI) guidelines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Universal screening twice during childhood: first screening performed between 9 and 11 years of age before puberty and second screening performed between 17 and 21 years of age after puberty, as lipid values normally vary during puberty. (See",
"      <a class=\"local\" href=\"#H6272034\">",
"       'Universal screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective screening for children at risk for CVD. (See",
"      <a class=\"local\" href=\"#H6272095\">",
"       'Selective screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H235228246\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of non-fasting, non-HDL C for all universal lipid screening, and for selective screening in children who are unlikely to comply with obtaining a fasting sample. Of note, the NHLBI Guidelines recommends using fasting lipid profile for selective screening. (See",
"      <a class=\"local\" href=\"#H235228246\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H960544\">",
"       'Which screening test?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/1\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/2\">",
"      Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/3\">",
"      McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol 2000; 20:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/4\">",
"      Juonala M, Viikari JS, R&ouml;nnemaa T, et al. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 2008; 28:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/5\">",
"      Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/6\">",
"      Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 2003; 290:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/7\">",
"      Raitakari OT, Juonala M, K&auml;h&ouml;nen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/8\">",
"      Frontini MG, Srinivasan SR, Xu J, et al. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 2008; 121:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/9\">",
"      Juonala M, Viikari JS, K&auml;h&ouml;nen M, et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol 2008; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/10\">",
"      Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007; 120:e189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/11\">",
"      Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. Am J Epidemiol 1991; 133:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/12\">",
"      Bao W, Srinivasan SR, Wattigney WA, et al. Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study. Arch Intern Med 1996; 156:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/13\">",
"      Schrott HG, Bucher KA, Clarke WR, Lauer RM. The Muscatine hyperlipidemia family study program. Prog Clin Biol Res 1979; 32:619.",
"     </a>",
"    </li>",
"    <li>",
"     Lipid Research Clinics Program. The Lipid Research Clinics Population Studies Data Book - Vol 1. Governement Printing Office; DHHS publication NO. (NIH) 80-1527, Washington, DC 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/15\">",
"      Morrison JA, Sprecher DL, Biro FM, et al. Serum testosterone associates with lower high-density lipoprotein cholesterol in black and white males, 10 to 15 years of age, through lowered apolipoprotein AI and AII concentrations. Metabolism 2002; 51:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/16\">",
"      Morrison JA, Barton BA, Biro FM, Sprecher DL. Sex hormones and the changes in adolescent male lipids: longitudinal studies in a biracial cohort. J Pediatr 2003; 142:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/17\">",
"      Berenson GS, Srinivasan SR, Cresanta JL, et al. Dynamic changes of serum lipoproteins in children during adolescence and sexual maturation. Am J Epidemiol 1981; 113:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/18\">",
"      Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation 2006; 114:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/19\">",
"      American Academy of Pediatrics. Committee on Nutrition. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/20\">",
"      American Academy of Pediatrics Committee on Nutrition: Statement on cholesterol. Pediatrics 1992; 90:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/21\">",
"      Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/22\">",
"      National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/23\">",
"      Gidding SS. New cholesterol guidelines for children? Circulation 2006; 114:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/24\">",
"      Kit BK, Carroll MD, Lacher DA, et al. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010. JAMA 2012; 308:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths --- United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010; 59:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/26\">",
"      de Ferranti SD. Declining cholesterol levels in US youths: a reason for optimism. JAMA 2012; 308:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/27\">",
"      US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics 2007; 120:e215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/28\">",
"      Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics 2010; 126:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/29\">",
"      McGill HC Jr, McMahan CA, Herderick EE, et al. Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 2000; 20:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/30\">",
"      Calonge N, Guirguis-Blake J. Screening for familial hypercholesterolaemia. BMJ 2007; 335:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/31\">",
"      Recommendations for preventive pediatric health care. Pediatrics 2007; 120:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/32\">",
"      Frontini MG, Srinivasan SR, Xu JH, et al. Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study). Am J Cardiol 2007; 100:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/33\">",
"      Srinivasan SR, Frontini MG, Xu J, Berenson GS. Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study. Pediatrics 2006; 118:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/34\">",
"      Rainwater DL, McMahan CA, Malcom GT, et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol 1999; 19:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/35\">",
"      Freedman DS, Wang YC, Dietz WH, et al. Changes and variability in high levels of low-density lipoprotein cholesterol among children. Pediatrics 2010; 126:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/36\">",
"      Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA 2012; 307:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/37\">",
"      Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA 2012; 307:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/38\">",
"      Newman TB, Pletcher MJ, Hulley SB. Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics 2012; 130:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/39\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/281/abstract/40\">",
"      Yu HH, Markowitz R, De Ferranti SD, et al. Direct measurement of LDL-C in children: performance of two surfactant-based methods in a general pediatric population. Clin Biochem 2000; 33:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16972 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_281=[""].join("\n");
var outline_f0_17_281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H896751\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H235228225\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728055\">",
"      ASSOCIATION BETWEEN PEDIATRIC DYSLIPIDEMIA AND ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H728251\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H235228232\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68566256\">",
"      Normative values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68566413\">",
"      Definition of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H432292\">",
"      - NHLBI panel definition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66231589\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H235228239\">",
"      LIPID SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4809106\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H960344\">",
"      - Family history: Insensitive predictor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6271992\">",
"      2011 NHLBI guidelines on pediatric lipid screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6272034\">",
"      - Universal screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6272095\">",
"      - Selective screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H960544\">",
"      Which screening test?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86015453\">",
"      - Confirmation testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6272158\">",
"      Screening controversies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H235228246\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H896751\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16972|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/24/44428\" title=\"table 1\">",
"      Causes of secondary dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/34/36397\" title=\"table 2\">",
"      NHANES Normal pediatric lipid values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/51/43836\" title=\"table 3\">",
"      NHLBI pediatric definition of lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/39/5757\" title=\"table 4\">",
"      NHLBI panel screening guidelines for pediatric dyslipidemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_282="Overview of nontuberculous mycobacterial pulmonary infections in children";
var content_f0_17_282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of nontuberculous mycobacterial pulmonary infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/282/contributors\">",
"     Andrea T Cruz, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/282/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/17/282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/17/282/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/17/282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1060354616\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/1\">",
"     1",
"    </a>",
"    ]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Nosocomial transmission has occurred with medical equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 130 species of have been identified, not all of which have been documented to cause disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. NTM pathogens are classified as rapidly growing or slowly growing (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ). Rapidly growing species grow within seven days and include",
"    <em>",
"     Mycobacterium fortuitum, M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. chelonae",
"    </em>",
"    . Slowly growing species require several weeks to grow and include",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC),",
"    <em>",
"     M. marinum,",
"    </em>",
"    and",
"    <em>",
"     M. kansasii",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenopathy, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in immune-compromised children).",
"   </p>",
"   <p>",
"    This topic will provide an overview of NTM pulmonary infections in children. NTM lymphadenitis, SSTI, disseminated infection, and bacteremia in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7722?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial skin and soft tissue infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354623\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common nontuberculous mycobacteria (NTM) species causing pulmonary disease in adults in the United States are",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC,",
"    <em>",
"     M. avium",
"    </em>",
"    and M.",
"    <em>",
"     intracellulare",
"    </em>",
"    ),",
"    <em>",
"     M. abscessus,",
"    </em>",
"    and",
"    <em>",
"     M. kansasii",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/10\">",
"     10",
"    </a>",
"    ]. Few data are available for children. However, MAC and",
"    <em>",
"     M. abscessus",
"    </em>",
"    are the species most frequently isolated from children with cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. In one series of 17 children with NTM pulmonary disease, MAC was more common in previously healthy children (n = 5) and",
"    <em>",
"     M. abscessus",
"    </em>",
"    or",
"    <em>",
"     M. chelonae",
"    </em>",
"    in children with cystic fibrosis (n = 8) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354630\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable, in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall prevalence of NTM disease appears to be increasing with time (possibly as a result of enhanced detection) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In case series, the prevalence of NTM among respiratory specimens from patients with cystic fibrosis ranges from 4 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,11,14,22\">",
"     2,11,14,22",
"    </a>",
"    ]. However, isolation of NTM from a respiratory specimen does not necessarily indicate NTM disease. In a prospective study of 682 sputum specimens from 106 children with cystic fibrosis, NTM were isolated from 6.6 percent, but only 1.9 percent had NTM disease (ie, clinical and functional decline in addition to isolation) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/22\">",
"     22",
"    </a>",
"    ]. Among patients with cystic fibrosis, NTM isolation is more common in teenagers and young adults than in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/11-13,15,22\">",
"     11-13,15,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NTM is transmitted through environmental sources. They are ubiquitous in the environment and have been isolated from water, soil, food products, and domestic and wild animals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. The respiratory or gastrointestinal tract is the usual portal of entry for NTM pulmonary disease. The incubation period is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354637\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis is the most common risk factor for pulmonary nontuberculous mycobacterial (NTM) disease in children in industrialized nations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. Screening patients with cystic fibrosis to make sure that NTM cultures are negative before initiation of antiinflammatory therapy with a macrolide antibiotic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link&amp;anchor=H12#H12\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Macrolide antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors for NTM pulmonary disease include polymorphisms in the cystic fibrosis transmembrane conductance regulatory genes without classic cystic fibrosis, polymorphisms in natural resistance-associated macrophage protein 1 (",
"    <em>",
"     NRAMP1",
"    </em>",
"    ) gene, and hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354644\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant nontuberculous mycobacterial (NTM) pulmonary disease is most often described in children with preexisting lung disease (eg, cystic fibrosis) and non-HIV immune deficiency and disseminated NTM disease; it is less common in patients with HIV infection and disseminated NTM disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link&amp;anchor=H1060363832#H1060363832\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features of NTM pulmonary disease are variable and nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Most patients have chronic or recurrent cough [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/29\">",
"     29",
"    </a>",
"    ]. Other pulmonary symptoms and signs include increased sputum production, dyspnea, hemoptysis, chest pain, rhonchi, crackles, wheezing, and stridor. Constitutional findings may include fever, fatigue, malaise, and weight loss; constitutional symptoms are more prevalent in immune deficient children and children with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of NTM pulmonary disease may depend, to some extent, upon the underlying medical problem(s).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 43 children (both healthy and with medical comorbidities) with NTM pulmonary disease, 60 percent had constitutional symptoms; fever was the most common, followed by weight loss and fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/31\">",
"       31",
"      </a>",
"      ]. Night sweats were uncommon.",
"     </li>",
"     <li>",
"      Among children with underlying lung disease, worsening of existing pulmonary symptoms (cough, increased sputum production, exercise intolerance, decline in pulmonary function), worsening nutritional status, or low-grade fever may be a clue pulmonary NTM disease. In patients with cystic fibrosis, chronic NTM infection is associated with worsening pulmonary function [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/32\">",
"       32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The clinical manifestations of pulmonary disease in patients with cystic fibrosis (including disease due to infection) are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a series of five children without underlying lung disease who developed culture-positive NTM pulmonary disease, the most common symptoms were wheezing or stridor that did not respond to bronchodilator or glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/33\">",
"       33",
"      </a>",
"      ]. All of the children were noted to have endobronchial lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hilar lymphadenopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354651\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the chest is necessary to diagnose nontuberculous mycobacterial (NTM) pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Radiographic findings in NTM pulmonary disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular or cavitary opacities on chest radiograph",
"     </li>",
"     <li>",
"      Multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (HRCT) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86444 \" href=\"UTD.htm?28/49/29463\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiographic features of NTM pulmonary disease may vary depending upon the underlying medical problem(s). The most common radiographic findings in otherwise healthy children include hilar lymphadenopathy and a tree-in-bud appearance associated with endobronchial spread [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/33\">",
"     33",
"    </a>",
"    ]. Infiltrates are more likely in children with constitutional symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/31\">",
"     31",
"    </a>",
"    ]. Pleural effusions are uncommon, and cavitary lesions in young children are rare.",
"   </p>",
"   <p>",
"    Radiographic features of NTM pulmonary disease also may vary depending on the causative species [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       M. avium",
"      </em>",
"      complex (MAC) &ndash; Apical fibrocavitary disease or nodular and interstitial nodular infiltrates often involving the right middle lobe or lingula",
"     </li>",
"     <li>",
"      <em>",
"       M. kansasii",
"      </em>",
"      &ndash; Cavitary infiltrates in the upper lobes",
"     </li>",
"     <li>",
"      <em>",
"       M. abscessus",
"      </em>",
"      &ndash; Multilobar, patchy, reticulonodular or mixed interstitial-alveolar opacities with an upper lobe predominance; cavitation may occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326135742\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762312726\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nontuberculous mycobacterial (NTM) pulmonary disease is established based on the combination of compatible clinical and radiographic findings the isolation of an NTM species in culture, and exclusion of other conditions in the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1060354665\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We agree with the American Thoracic Society and Infectious Disease Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    criteria for the diagnosis of NTM pulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Both the clinical and microbiologic criteria must be fulfilled.",
"   </p>",
"   <p>",
"    When NTM is isolated from a patient with underlying lung disease, it can be difficult to determine whether NTM represents a true pathogen, colonization, or a contaminant. Consultation with an expert in infectious diseases",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary medicine may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326135601\">",
"    <span class=\"h3\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;NTM pulmonary disease may be suspected in (see",
"    <a class=\"local\" href=\"#H1060354644\">",
"     'Clinical features'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,23,33\">",
"     2,23,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with underlying pulmonary disease with worsening of pulmonary",
"      <span class=\"nowrap\">",
"       symptoms/function,",
"      </span>",
"      weight loss, or low-grade fever, in whom other causes have been excluded",
"     </li>",
"     <li>",
"      Children with cystic fibrosis and exacerbation of pulmonary symptoms that does not respond to routine treatment and antipseudomonal antibiotics (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"       \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Children with non-HIV immune deficiency and disseminated NTM disease",
"     </li>",
"     <li>",
"      Previously healthy children with wheezing or stridor that is unresponsive to bronchodilator or glucocorticoid therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923504671\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings in NTM pulmonary disease include (see",
"    <a class=\"local\" href=\"#H1060354651\">",
"     'Radiographic features'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular or cavitary opacities on chest radiograph, or",
"     </li>",
"     <li>",
"      Multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (HRCT) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86444 \" href=\"UTD.htm?28/49/29463\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with underlying pulmonary disease, it is important to compare radiographs and computed tomography findings with previous studies to determine if there has been a change. It can be difficult to differentiate between worsening of the primary pulmonary disorder and NTM pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762312692\">",
"    <span class=\"h3\">",
"     Microbiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When NTM pulmonary disease is suspected, pulmonary specimens should be sent for histopathology, acid-fast bacillus (AFB) staining, and mycobacterial culture (as well as bacterial and fungal stains and cultures as clinically indicated).",
"   </p>",
"   <p>",
"    It is helpful to discuss specimen collection, transport, and culture processing with the microbiology laboratory before sending tissue or fluid to the laboratory. Most NTM species will not grow in traditional bacterial culture media; rapidly growing NTM species (eg,",
"    <em>",
"     M. abscessus",
"    </em>",
"    ) are an exception [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/34\">",
"     34",
"    </a>",
"    ]. Techniques for maximizing the yield of cultures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       AFB staining",
"      </strong>",
"      &ndash; AFB staining cannot distinguish among NTM species or between NTM species and",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      . Negative AFB stains do not exclude a diagnosis of mycobacterial disease. In a prospective series of 104 positive NTM cultures from patients with cystic fibrosis, the AFB smear was positive only in one-third [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/11\">",
"       11",
"      </a>",
"      ]. Positive AFB stains increase the likelihood that an NTM isolate is clinically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H3#H3\">",
"       \"Microbiology of nontuberculous mycobacteria\", section on 'Microscopy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2118471755\">",
"       'Clinical significance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Culture",
"      </strong>",
"      &ndash; A positive NTM culture (from sputum, bronchial wash or lavage, transbronchial or other lung biopsy) in a patient with compatible clinical and radiographic findings establishes the diagnosis of NTM pulmonary disease (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ). Identification of the NTM species is necessary to determine the clinical significance and appropriate antimycobacterial regimen.",
"      <br/>",
"      <br/>",
"      The importance of obtaining adequate specimens for culture and proper processing cannot be over-emphasized. The yield of cultures may be reduced by insufficient quality (eg, nasopharyngeal swab rather than expectorated sputum) or quantity of a respiratory specimen [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"       \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The time (in days) to detection of mycobacterial growth may help to distinguish between NTM species.",
"      <em>",
"       M. abscessus",
"      </em>",
"      grows within seven days, whereas MAC and",
"      <em>",
"       M. kansasii",
"      </em>",
"      require several weeks for growth.",
"     </li>",
"     <li>",
"      <strong>",
"       Rapid diagnostic tests",
"      </strong>",
"      &ndash; Rapid methods for identification of NTM species include high-pressure liquid chromatography (HPLC) and polymerase chain reaction (PCR) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"       2",
"      </a>",
"      ]. HPLC examines the mycolic acid fingerprint patterns that differ among most species or complexes of mycobacteria and can be used to speciate NTM, including rapidly growing mycobacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/36\">",
"       36",
"      </a>",
"      ]. However, HPLC cannot reliably differentiate between",
"      <em>",
"       M. abscessus",
"      </em>",
"      and",
"      <em>",
"       M. chelonae",
"      </em>",
"      .",
"      <br/>",
"      <br/>",
"      PCR can be useful for determining which species of NTM is causing the infection before identification in culture. Nucleic acid probes for MAC and",
"      <em>",
"       M. kansasii",
"      </em>",
"      are commercially available. However, there is little experience with PCR and other molecular modalities for the diagnosis of NTM pulmonary disease in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2118471755\">",
"    <span class=\"h3\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;When NTM is isolated from a child with pulmonary symptoms and signs, the clinical significance of the isolate must be determined. The pathogenicity of the various NTM species varies substantially. The possibility that NTM was isolated as a result of contamination or represents colonization of diseased lung also must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Consultation with a specialist in infectious diseases may be helpful in determining the clinical significance of the isolate.",
"   </p>",
"   <p>",
"    Factors that increase the likelihood of clinical significance include recovery from multiple specimens, recovery in large quantities (ie, AFB positive specimens), and recovery from a normally sterile site [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354665\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important considerations in the differential diagnosis of nontuberculous mycobacterial (NTM) pulmonary disease in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression of primary pulmonary disease (eg, worsening bronchiectasis in patients with cystic fibrosis) &ndash; Progression of primary pulmonary disease is rarely associated with extrapulmonary manifestations, including bacteremia.",
"     </li>",
"     <li>",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      &ndash; The cavitary appearance and endobronchial spread of NTM can mimic radiographic findings of",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      . It is important to distinguish tuberculous from NTM pulmonary disease because they require different treatments; in addition,",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      requires contact tracing, whereas NTM does not.",
"      <br/>",
"      <br/>",
"      In a child with risk factors for",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      and acid-fast bacillus (AFB) positive sputum, NTM and",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      must be differentiated by mycobacterial culture and speciation. In a series of respiratory specimens from 17 children in Texas who met criteria for diagnosis of NTM pulmonary disease (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ),",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      was isolated more frequently than all other mycobacterial species (23 versus 17 specimens) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It may be necessary to initiate empiric therapy before the distinction between NTM and",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      is made. In such cases, coverage for both pathogens is provided in a multi-drug regimen. (See",
"      <a class=\"local\" href=\"#H1326136013\">",
"       'NTM and M. tuberculosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Other forms of nodular lung disease, including disseminated fungal disease (",
"      <a class=\"graphic graphic_table graphicRef70568 \" href=\"UTD.htm?29/20/30028\">",
"       table 3",
"      </a>",
"      ) &ndash; Clinical features (eg, exposures) may help to differentiate NTM from other nodular lung diseases, but microbiologic studies are necessary for definitive diagnosis.",
"     </li>",
"     <li>",
"      <em>",
"       Pneumocystis jirovecii",
"      </em>",
"      pneumonia &ndash; The ground-glass appearance occasionally seen in NTM pulmonary disease can mimic",
"      <em>",
"       P. jirovecii",
"      </em>",
"      pneumonia. Microbiologic studies can be helpful in differentiating between NTM and",
"      <em>",
"       P. jiroveci",
"      </em>",
"      pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link&amp;anchor=H14#H14\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354672\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762312992\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the side effect profile of the medications used to treat nontuberculous mycobacterial (NTM) pulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ), it is essential to make sure that children meet the criteria for diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ) before initiating therapy.",
"   </p>",
"   <p>",
"    Antimycobacterial treatment generally is warranted for children who meet clinical and microbiologic criteria for NTM pulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ). However, the potential risks and benefits of antimycobacterial therapy disease must be considered before initiating treatment.",
"   </p>",
"   <p>",
"    As an example, in an adolescent with cystic fibrosis who is awaiting lung transplantation in whom",
"    <em>",
"     M. abscessus",
"    </em>",
"    is isolated, the benefits of decreased burden of",
"    <em>",
"     M. abscessus",
"    </em>",
"    and potential decreased risk of recurrence post-transplant may outweigh the adverse effects of parenteral multi-drug therapy with ototoxic and nephrotoxic drugs. On the other hand, the risks of therapy may outweigh the benefits in a young child in whom a potentially non-pathogenic species or contaminant (eg,",
"    <em>",
"     M. mucogenicum",
"    </em>",
"    ) is isolated from a respiratory specimen. (See",
"    <a class=\"local\" href=\"#H1060354693\">",
"     'M. abscessus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Susceptibility testing is recommended for clinically significant NTM pulmonary isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. However, with the exception of macrolides in the treatment of",
"    <em>",
"     M. avium",
"    </em>",
"    complex (MAC), drug susceptibility testing for NTM has less correlation with in vivo response than for other pathogens.",
"   </p>",
"   <p>",
"    Given that the diagnostic criteria for NTM pulmonary disease require sequential sputum samples (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ), speciation and drug susceptibility results often are available before initiation of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it may be necessary to initiate empiric therapy before speciation is complete, particularly when",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    cannot be excluded. (See",
"    <a class=\"local\" href=\"#H1762312726\">",
"     'Diagnostic criteria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1060354665\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2118470656\">",
"    <span class=\"h2\">",
"     Antimycobacterial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326136013\">",
"    <span class=\"h3\">",
"     NTM and M. tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children in whom the distinction between NTM and",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    remains uncertain after clinical, radiographic, and initial laboratory evaluation (eg, children with risk factors for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    and positive smears for acid-fast bacilli), we suggest empiric treatment with the following regimen until speciation is available (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       Isoniazid",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       Rifampin",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      A macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on in vitro susceptibilities, this regimen provides initial empiric coverage for",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    , and two NTM species frequently isolated from children with NTM pulmonary disease (MAC and",
"    <em>",
"     M. kansasii",
"    </em>",
"    ). It is consistent with the recommendations of the American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America and the American Academy of Pediatrics Committee on Infectious Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The regimen can be tailored according to speciation and susceptibility testing when these results are available. (See",
"    <a class=\"local\" href=\"#H1762312692\">",
"     'Microbiologic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354686\">",
"    <span class=\"h3\">",
"     M. avium complex",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923504373\">",
"    <span class=\"h4\">",
"     HIV-negative children",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that HIV-negative children with nodular or noncavitating bronchiectatic MAC lung disease be treated with a regimen that includes (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ),",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      A rifamycin (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"       rifabutin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The medications are administered three times per week until the sputum cultures have been negative for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. Three-times-weekly dosing for patients with nodular or nonsevere bronchiectatic MAC disease is supported by several prospective studies in adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that HIV-negative children with extensive bronchiectasis or fibrocavitary MAC lung disease be treated with a regimen that includes (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ),",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      A rifamycin (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"       rifabutin",
"      </a>",
"      ),",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      An aminoglycoside (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"       streptomycin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three drugs should be administered daily. The aminoglycoside is also administered daily in children; however, in older adolescents,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    may be administered three times per week. In a randomized study in adult patients with tuberculous or nontuberculous mycobacterial infections, the administration of amikacin 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times per week was not associated with increased toxicity compared with daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/40\">",
"     40",
"    </a>",
"    ]. The aminoglycoside should be discontinued after eight weeks; the remainder of the drugs should be continued until the child&rsquo;s sputum cultures have been negative for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations for treatment of MAC pulmonary disease in HIV-negative children are based upon in vitro susceptibilities, and observational studies in HIV-negative adult patients, in which multi-drug treatment with a macrolide-containing regimen was associated with clearance of MAC from sputum in &gt;60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/37,41,42\">",
"     37,41,42",
"    </a>",
"    ]. They are consistent with the recommendations of the American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America and the American Academy of Pediatrics Committee on Infectious Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1923504380\">",
"    <span class=\"h4\">",
"     HIV-positive children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory symptoms are uncommon among HIV-infected children with disseminated MAC, and isolated pulmonary disease is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/28\">",
"     28",
"    </a>",
"    ]. We suggest that children with HIV infections and MAC who meet the diagnostic criteria for pulmonary disease (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 2",
"    </a>",
"    ) be treated in the same manner as those with disseminated infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=see_link&amp;anchor=H1590632073#H1590632073\">",
"     \"Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children\", section on 'Antimycobacterial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354693\">",
"    <span class=\"h3\">",
"     M. abscessus",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children with",
"    <em>",
"     M. abscessus",
"    </em>",
"    pulmonary disease, we suggest initial treatment with (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      or a carbapenem (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       meropenem",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The regimen can be tailored according to drug susceptibilities, bearing in mind that in vitro susceptibilities may not correlate with clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. The initial regimen should include three drugs to which there is documented susceptibility.",
"   </p>",
"   <p>",
"    The goal of",
"    <em>",
"     M. abscessus",
"    </em>",
"    therapy should not be microbiologic eradication. Instead, symptomatic and radiographic improvements should be the endpoints of therapy. Therapy should include three drugs to which there is documented susceptibility; after four to eight weeks of intensification therapy, two drugs may be used to complete therapy (usually for a total duration of 6 to 12 months). The duration of therapy may be limited by the patient&rsquo;s ability to tolerate the medications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"    <em>",
"     M. abscessus",
"    </em>",
"    has a predilection for infecting diseased lungs and is difficult to eradicate; cure is generally possible only with surgical resection when lung disease is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1060354714\">",
"     'Surgical therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    and fluoroquinolones can been used for patients with refractory",
"    <em>",
"     M. abscessus",
"    </em>",
"    pulmonary disease. However, the utility of linezolid in children may be limited by bone marrow suppression or optic neuritis, and high rates of fluoroquinolone resistance have been reported in children with no previous exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354707\">",
"    <span class=\"h3\">",
"     M. kansasii",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    <strong>",
"     -susceptible",
"    </strong>",
"    <em>",
"     M. kansasii",
"    </em>",
"    pulmonary disease be treated with (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       Isoniazid",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       Rifampin",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      ,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      A macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    -susceptible",
"    <em>",
"     M. kansasii",
"    </em>",
"    should continue until sputum cultures have been negative for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that children with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    <strong>",
"     -resistant",
"    </strong>",
"    isolates be treated with three drugs based upon in vitro susceptibilities. Potential agents include macrolides, fluoroquinolones, aminoglycosides, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ). Treatment for rifampin-resistant",
"    <em>",
"     M. kansasii",
"    </em>",
"    should continue until sputum cultures have been negative for 12 to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no randomized trials of treatment for",
"    <em>",
"     M. kansasii",
"    </em>",
"    . In in vitro studies,",
"    <em>",
"     M. kansa",
"    </em>",
"    sii is susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    , fluoroquinolones, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"     rifabutin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. In observational studies, multi-drug regimens that included",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    were associated with clearance of",
"    <em>",
"     M. kansasii",
"    </em>",
"    within four months in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Relapse, which was rare, was associated with development of rifampin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354714\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection may be required as an adjunct to antimycobacterial therapy for children with MAC with isolated cavities,",
"    <em>",
"     M. abscessus",
"    </em>",
"    , failure to convert sputum cultures after six months, or patients who cannot tolerate antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1060354721\">",
"     'Monitoring response to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with limited pulmonary disease, surgical resection can be curative. In patients with extensive pulmonary disease, surgical resection may be performed in an attempt to decrease organism burden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060354721\">",
"    <span class=\"h2\">",
"     Monitoring response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are being treated for pulmonary NTM disease should be monitored by monthly symptom screening, sputum analyses, and pulmonary function tests.",
"   </p>",
"   <p>",
"    We do not routinely monitor response to therapy for pulmonary NTM disease with serial computed tomography of the chest, although repeat imaging may be warranted one to two months after initiation of therapy and for children who have clinical deterioration during therapy. Children with pulmonary NTM disease, by virtue of their underlying medical conditions, are likely to have higher cumulative radiation exposure at baseline than children without such conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful treatment of patients with MAC pulmonary disease is indicated by clinical improvement within three to six months and negative sputum cultures within 12 months of initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/41\">",
"     41",
"    </a>",
"    ]. Possible reasons for failure to respond within these timeframes include poor",
"    <span class=\"nowrap\">",
"     adherence/drug",
"    </span>",
"    intolerance, macrolide resistance, or anatomic limitations (eg, focal cystic or cavitary disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]. An alternative medication regimen or surgery may be warranted.",
"   </p>",
"   <p>",
"    The endpoint of therapy for",
"    <em>",
"     M. abscessus",
"    </em>",
"    is symptomatic improvement and prevention of disease progression rather than microbiologic eradication. Microbiologic eradication is possible only with surgical resection of limited lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1060354693\">",
"     'M. abscessus'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1060354714\">",
"     'Surgical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1762313163\">",
"    <span class=\"h2\">",
"     Monitoring adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimycobacterial agents that are used to treat NTM pulmonary infections often are difficult to tolerate and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/18/26917?source=see_link\">",
"     streptomycin",
"    </a>",
"    , optic neuropathy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , and hepatotoxicity with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    . The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link\">",
"     \"Aminoglycosides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=see_link\">",
"     \"Isoniazid: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=see_link\">",
"     \"Isoniazid hepatotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common adverse effects of antimycobacterial medications are provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It may be challenging to determine which medication is responsible for a given reaction because treatment of pulmonary NTM requires multiple medications. The medical comorbidities of children predisposed to pulmonary NTM infection further complicate the issue. Children with comorbid medical conditions may require additional medications that can interact with antimycobacterial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/18\">",
"     18",
"    </a>",
"    ]. They also may have baseline hepatic or renal dysfunction, which may decrease medication tolerance.",
"   </p>",
"   <p>",
"    Most adverse effects are monitored clinically by assessing the patient for symptoms (eg, dizziness, vomiting, etc). However, specific parameters should be monitored as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      &ndash; Periodic alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) during the first three months of therapy. Baseline electrocardiogram to evaluate for prolonged QT interval is suggested before the initiation of therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/31/12792?source=see_link\">",
"       Rifabutin",
"      </a>",
"      &ndash; Periodic white blood cell (WBC) counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       Amikacin",
"      </a>",
"      &ndash; Periodic amikacin levels.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      &ndash; Periodic blood counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      &ndash; Periodic blood counts.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      &ndash; Periodic blood counts and eye examinations by an ophthalmologist.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       Ethambutol",
"      </a>",
"      - periodic eye examinations by an ophthalmologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    , a macrolide, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"     ethambutol",
"    </a>",
"    , we suggest baseline laboratory evaluation as indicated above. Thereafter, the need for subsequent laboratory evaluation should be driven by symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination findings; scheduled laboratory evaluation may not be needed unless patients are receiving other marrow-suppressive or potentially hepatotoxic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060355551\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nontuberculous mycobacterial (NTM) pulmonary disease in children usually affects patients with underlying lung disease, particularly cystic fibrosis.",
"      <em>",
"       Mycobacterium avium complex",
"      </em>",
"      (MAC) and",
"      <em>",
"       M. abscessus",
"      </em>",
"      are the species most frequently isolated from children with NTM pulmonary disease. (See",
"      <a class=\"local\" href=\"#H1060354637\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1060354623\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of NTM pulmonary disease are variable and nonspecific. Most patients have chronic or recurrent cough. Other findings may include increased sputum, dyspnea, hemoptysis, chest pain, abnormal auscultatory findings (eg, crackles, wheezing, stridor), fever, fatigue, and weight loss. (See",
"      <a class=\"local\" href=\"#H1060354644\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings in NTM pulmonary disease include nodular or cavitary opacities on chest radiograph and multifocal bronchiectasis with multiple small nodules on high-resolution computed tomography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86444 \" href=\"UTD.htm?28/49/29463\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1060354651\">",
"       'Radiographic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of NTM pulmonary disease requires a combination of clinical symptoms, compatible radiographic findings, isolation of NTM, and exclusion of other conditions in the differential diagnosis (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1326135742\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is particularly important to distinguish tuberculous from NTM pulmonary disease because they have different therapeutic and public health implications. Additional considerations in the differential diagnosis of NTM pulmonary disease include progression of primary pulmonary disease, other forms of nodular lung disease (",
"      <a class=\"graphic graphic_table graphicRef70568 \" href=\"UTD.htm?29/20/30028\">",
"       table 3",
"      </a>",
"      ), and",
"      <em>",
"       Pneumocystis jirovecii",
"      </em>",
"      pneumonia. Microbiologic studies are necessary to distinguish among the possibilities. (See",
"      <a class=\"local\" href=\"#H1060354665\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimycobacterial treatment generally is warranted for children who meet clinical and microbiologic criteria for NTM pulmonary disease (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 2",
"      </a>",
"      ). However, the potential risks and benefits of antimycobacterial therapy disease must be considered before initiating treatment. (See",
"      <a class=\"local\" href=\"#H1762312992\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children in whom the distinction between NTM and",
"      <em>",
"       M. tuberculosis",
"      </em>",
"      remains uncertain, we suggest empiric treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/24/38278?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/52/17225?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      , and a macrolide (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       azithromycin",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 4",
"      </a>",
"      ) pending speciation and results of antimycobacterial susceptibility testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1326136013\">",
"       'NTM and M. tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of MAC pulmonary disease in children depends upon the severity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children with nodular or noncavitating bronchiectatic disease, we suggest treatment with a macrolide, a rifamycin, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Therapy is administered three times per week and continued until sputum cultures have been negative for at least one year.",
"     </li>",
"     <li>",
"      For children with cavitary or extensive bronchiectatic disease, we suggest treatment with a macrolide, a rifamycin,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/13/6357?source=see_link\">",
"       ethambutol",
"      </a>",
"      , and an aminoglycoside (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Therapy is administered daily. The aminoglycoside is discontinued after eight weeks; the other drugs are continued until the child&rsquo;s sputum cultures have been negative for at least one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with",
"      <em>",
"       M. abscessus",
"      </em>",
"      pulmonary disease, we suggest initial treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/37/30297?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      and either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/32/29188?source=see_link\">",
"       cefoxitin",
"      </a>",
"      or a carbapenem (",
"      <a class=\"graphic graphic_table graphicRef86161 \" href=\"UTD.htm?8/4/8271\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The endpoint of therapy for",
"      <em>",
"       M. abscessus",
"      </em>",
"      is symptomatic improvement and prevention of disease progression rather than microbiologic eradication.",
"     </li>",
"     <li>",
"      Surgical resection may be required as an adjunct to antimycobacterial therapy for children with MAC with isolated cavities",
"      <em>",
"       M. abscessus",
"      </em>",
"      , failure to convert sputum cultures after six months, or patients who cannot tolerate antimycobacterial therapy. (See",
"      <a class=\"local\" href=\"#H1060354714\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who are being treated for pulmonary NTM disease should be monitored by monthly symptom screening, sputum analyses, and pulmonary function tests. (See",
"      <a class=\"local\" href=\"#H1060354721\">",
"       'Monitoring response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/1\">",
"      Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/2\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/3\">",
"      Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/4\">",
"      Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/5\">",
"      Al Soub H, Al Maslamani M, Al Khuwaiter J, et al. Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature. Pediatr Infect Dis J 2009; 28:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/6\">",
"      McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/7\">",
"      Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria: (atypical mycobacteria, mycobacteria other than Mycobacterium tuberculosis. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.759.",
"    </li>",
"    <li>",
"     Mycobacterium. In: List of Prokaryotic names with Standing in Nomenclature. file://www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/10\">",
"      Winthrop KL, Albridge K, South D, et al. The clinical management and outcome of nail salon-acquired Mycobacterium fortuitum skin infection. Clin Infect Dis 2004; 38:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/11\">",
"      Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009; 47:4124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/12\">",
"      Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/13\">",
"      Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/14\">",
"      Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/15\">",
"      Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005; 43:3467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/16\">",
"      Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/17\">",
"      Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/18\">",
"      Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/19\">",
"      Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/20\">",
"      Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/21\">",
"      Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/22\">",
"      Fauroux B, Delaisi B, Cl&eacute;ment A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997; 16:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/23\">",
"      Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med 2009; 30:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/24\">",
"      Colombo RE, Hill SC, Claypool RJ, et al. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2010; 137:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/25\">",
"      Koh WJ, Kwon OJ, Kim EJ, et al. NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases. Chest 2005; 128:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/26\">",
"      Unal E, Yen C, Saiman L, et al. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2006; 12:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/27\">",
"      Aronchick JM, Miller WT Jr. Disseminated nontuberculous mycobacterial infections in immunosuppressed patients. Semin Roentgenol 1993; 28:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/28\">",
"      Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/29\">",
"      Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271.",
"     </a>",
"    </li>",
"    <li>",
"     Tebruegge M, Curtis N. Mycobacterium species non-tuberculosis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.786.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/31\">",
"      Nolt D, Michaels MG, Wald ER. Intrathoracic disease from nontuberculous mycobacteria in children: two cases and a review of the literature. Pediatrics 2003; 112:e434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/32\">",
"      Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/33\">",
"      Freeman AF, Olivier KN, Rubio TT, et al. Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children. Pediatr Pulmonol 2009; 44:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/34\">",
"      Murillo J, Torres J, Bofill L, et al. Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculpture. The Venezuelan Collaborative Infectious and Tropical Diseases Study Group. Arch Dermatol 2000; 136:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/35\">",
"      Somoskovi A, Mester J, Hale YM, et al. Laboratory diagnosis of nontuberculous mycobacteria. Clin Chest Med 2002; 23:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/36\">",
"      Butler WR, Ahearn DG, Kilburn JO. High-performance liquid chromatography of mycolic acids as a tool in the identification of Corynebacterium, Nocardia, Rhodococcus, and Mycobacterium species. J Clin Microbiol 1986; 23:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/37\">",
"      Griffith DE, Brown BA, Girard WM, et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001; 32:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/38\">",
"      Griffith DE, Brown BA, Murphy DT, et al. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998; 178:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/39\">",
"      Griffith DE, Brown BA, Cegielski P, et al. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin Infect Dis 2000; 30:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/40\">",
"      Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/41\">",
"      Wallace RJ Jr, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996; 153:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/42\">",
"      Tanaka E, Kimoto T, Tsuyuguchi K, et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/43\">",
"      Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/44\">",
"      da Silva Telles MA, Chimara E, Ferrazoli L, Riley LW. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 2005; 54:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/45\">",
"      Guna R, Mu&ntilde;oz C, Dom&iacute;nguez V, et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. J Antimicrob Chemother 2005; 55:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/46\">",
"      Alcaide F, Calatayud L, Sant&iacute;n M, Mart&iacute;n R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 2004; 48:4562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/47\">",
"      Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/48\">",
"      Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/49\">",
"      Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/50\">",
"      Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983; 38:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/17/282/abstract/51\">",
"      Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007; 357:2277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85894 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_282=[""].join("\n");
var outline_f0_17_282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1060355551\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354616\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354623\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354630\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354637\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354644\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354651\">",
"      RADIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1326135742\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1762312726\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1326135601\">",
"      - Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1923504671\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1762312692\">",
"      - Microbiologic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2118471755\">",
"      - Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354665\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354672\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1762312992\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2118470656\">",
"      Antimycobacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1326136013\">",
"      - NTM and M. tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354686\">",
"      - M. avium complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1923504373\">",
"      HIV-negative children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1923504380\">",
"      HIV-positive children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354693\">",
"      - M. abscessus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354707\">",
"      - M. kansasii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354714\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1060354721\">",
"      Monitoring response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1762313163\">",
"      Monitoring adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060355551\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/85894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85894|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/49/29463\" title=\"diagnostic image 1\">",
"      HRCT NTM lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/85894|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/48/11020\" title=\"table 2\">",
"      Criteria for NTM diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30028\" title=\"table 3\">",
"      Ddx miliary infiltrates on CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/4/8271\" title=\"table 4\">",
"      Treatment NTM children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41943?source=related_link\">",
"      Isoniazid hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19142?source=related_link\">",
"      Isoniazid: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37257?source=related_link\">",
"      Overview of disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7722?source=related_link\">",
"      Overview of nontuberculous mycobacterial skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_17_283="Core cross cultural issues";
var content_f0_17_283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Core cross-cultural issues",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Styles of communication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mistrust and prejudice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decision-making and family dynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traditions, customs, and spirituality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sexual and gender issues",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_283=[""].join("\n");
var outline_f0_17_283=null;
var title_f0_17_284="Family needs CSHCN";
var content_f0_17_284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Families' healthcare recommendations for children with special health care needs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Service delivery recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improve accessibility and availability of healthcare services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop centralized information and referral sources for families and clinicians",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide a case manager to access and coordinate resources and services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Centralize services for children with chronic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide comprehensive care to meet the needs of the whole child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide appropriate referrals and improve access to qualified, knowledgeable clinicians",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improve methods of treatment for children with chronic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coordinate services and resources more effectively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Include families in planning services and staffing programs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure quality of services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide patient and family advocates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family-centered care recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide services and programs that meet the child and family's particular needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improve communication and working relationships between clinicians and families",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide flexible, family-oriented services and programs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess family strengths and resources when planning care",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Garwick A, Kohrman C, Wolman C, Blum R. Arch Pediatr Adolesc Med 1998; 152:440.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_284=[""].join("\n");
var outline_f0_17_284=null;
var title_f0_17_285="High fiber foods";
var content_f0_17_285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High fiber foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fiber (grams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cereal (1/2 cup serving)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fiber One",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100% Bran",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All Bran",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bran Buds",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kashi Go Lean&nbsp;",
"       </td>",
"       <td>",
"        8 to 10&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kellogg's Complete Bran Flakes",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grape Nuts",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raisin Bran*",
"       </td>",
"       <td>",
"        3 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cracklin' Oat Bran*",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100% Whole Grain Wheat Chex",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fruit and Fibre",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Great Grains",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frosted Mini Wheats",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kellogg's Low Fat Granola",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fruit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pear (one)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strawberries (1 cup)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apple (one, with skin)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dried fruits (eg, raisins) (3 Tablespoons)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papaya (one)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Vegetables (cooked unless indicated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pinto, kidney, black,lima beans (1/2 cup)",
"       </td>",
"       <td>",
"        4 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweet potato (1 medium)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lentils (1/2 cup)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jicama (1/2 raw)",
"       </td>",
"       <td>",
"        3 to 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Baked potato with skin (medium)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corn (1/2 cup)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peas (1/2 cup)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These cereals are also high in sugar (15 to 20 grams/serving).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_285=[""].join("\n");
var outline_f0_17_285=null;
var title_f0_17_286="Clinical decisions and prognosis";
var content_f0_17_286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Impact of prognosis on selected clinical decisions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Prognosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical decision to be considered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;4 to 6 weeks",
"       </td>",
"       <td>",
"        Depression at end of life",
"       </td>",
"       <td>",
"        Use of methylphenidate to treat depression; a selective serotonin reuptake inhibitor requires four to six weeks to take effect",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;3 months",
"       </td>",
"       <td>",
"        Hyperlipidemia",
"       </td>",
"       <td>",
"        Discontinuation of statins",
"        <sup>",
"         [2,3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &gt;3 months",
"       </td>",
"       <td>",
"        Spinal metastases",
"       </td>",
"       <td>",
"        Surgery for spinal cord compression due to metastatic cancer",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;6 months",
"       </td>",
"       <td>",
"        Hospice",
"       </td>",
"       <td>",
"        Referral to hospice",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;1 to 2 years",
"       </td>",
"       <td>",
"        Asymptomatic abdominal aortic aneurysm",
"       </td>",
"       <td>",
"        Non-operative management of asymptomatic abdominal aortic aneurysm",
"        <sup>",
"         [5-8]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;2 to 3 years",
"       </td>",
"       <td>",
"        Prevention macrovascular complications in diabetes mellitus",
"       </td>",
"       <td>",
"        Blood pressure/lipid control in diabetes mellitus unlikely to prevent macrovascular complications",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;2 to 3 years",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        Lowering blood pressure &lt;140/80 unlikely to improve cardiovascular outcomes",
"        <sup>",
"         [2,10]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;5 years",
"       </td>",
"       <td>",
"        Screening for breast cancer",
"       </td>",
"       <td>",
"        Discontinuation of breast cancer screening",
"        <sup>",
"         [11-14]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;5 years",
"       </td>",
"       <td>",
"        Heart valve replacement",
"       </td>",
"       <td>",
"        Stented bioprosthetic heart valve may be preferable to a metallic valve",
"        <sup>",
"         [15]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;5 years",
"       </td>",
"       <td>",
"        Glycemic control in diabetes",
"       </td>",
"       <td>",
"        Limited benefit to lowering target for A1C to &lt;8 percent",
"        <sup>",
"         [2,9]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;7 years",
"       </td>",
"       <td>",
"        Screening for colorectal cancer",
"       </td>",
"       <td>",
"        Discontinuation of colorectal cancer screening",
"        <sup>",
"         [11,16-18]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        &lt;8 years",
"       </td>",
"       <td>",
"        Prevention microvascular complications in diabetes",
"       </td>",
"       <td>",
"        Tight glycemic control in diabetes mellitus is unlikely to prevent microvascular complications",
"        <sup>",
"         [2,9,19,20]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. JAMA 2001; 285:2898.",
"       </li>",
"       <li>",
"        Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166:605.",
"       </li>",
"       <li>",
"        Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 2005; 8:876.",
"       </li>",
"       <li>",
"        Abrahm JL, Banffy MB, Harris MB. Spinal cord compression in patients with advanced metastatic cancer: \"all I care about is walking and living my life\". JAMA 2008; 299:937.",
"       </li>",
"       <li>",
"        Fillinger M. Who should we operate on and how do we decide: predicting rupture and survival in patients with aortic aneurysm. Semin Vasc Surg 2007; 20:121.",
"       </li>",
"       <li>",
"        Conway KP, Byrne J, Townsend M, Lane IF. Prognosis of patients turned down for conventional abdominal aortic aneurysm repair in the endovascular and sonographic era: Szilagyi revisited? J Vasc Surg 2001; 33:752.",
"       </li>",
"       <li>",
"        Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287:2968.",
"       </li>",
"       <li>",
"        Mohan IV, Harris PL. When not to operate for abdominal aortic aneurysms. Semin Interv Cardiol 2000; 5:15.",
"       </li>",
"       <li>",
"        Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51:S265.",
"       </li>",
"       <li>",
"        Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.",
"       </li>",
"       <li>",
"        Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005; 118:1078.",
"       </li>",
"       <li>",
"        Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011; 365:1025.",
"       </li>",
"       <li>",
"        Breast cancer screening in older women. American Geriatrics Society Clinical Practice Committee. J Am Geriatr Soc 2000; 48:842.",
"       </li>",
"       <li>",
"        U.S. Preventive Services Task Force: Screening for Breast Cancer. U.S. Preventive Services Task Force 2009.",
"       </li>",
"       <li>",
"        Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010; 55:2413.",
"       </li>",
"       <li>",
"        Walter LC, Lindquist K, Nugent S, et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med 2009; 150:465.",
"       </li>",
"       <li>",
"        Colon cancer screening (USPSTF recommendation). U.S. Preventive Services Task Force. J Am Geriatr Soc 2000; 48:333.",
"       </li>",
"       <li>",
"        U.S. Preventive Services Task Force: Screening for Colorectal Cancer. U.S. Preventive Services Task Force 2008.",
"       </li>",
"       <li>",
"        Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008; 149:11.",
"       </li>",
"       <li>",
"        Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53:298.",
"       </li>",
"      </ol>",
"      <br>",
"       Modified with permission from: Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults. A systematic review. JAMA 2012; 307:182. Copyright &copy; 2012 American Medical Association. All rights reserved.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_286=[""].join("\n");
var outline_f0_17_286=null;
var title_f0_17_287="Diagnosis and management of a small renal mass";
var content_f0_17_287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Diagnosis and management of a small renal mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 473px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging; RCC: renal cell carcinoma.",
"     <br/>",
"     * Percutaneous biopsy is an option for the surgical patient if preoperative confirmation of the diagnosis is requested.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Options are to repeat the biopsy or to proceed with treatment assuming it is an RCC.",
"     <br/>",
"     &Delta; Surgery is the preferred treatment if RCC is documented. Thermal ablation is appropriate for patients who are not surgical candidates. The choice between these options is guided by the available local expertise and patient preference.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_17_287=[""].join("\n");
var outline_f0_17_287=null;
